HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
A T L A S
/ Second supplemented edition /
Interpretable prognosis for susceptibility to active anti-cancer molecular
forms, based on amides/carboxylic acids - hydrolysis derivatives of
natural nitrile glycosides, of transcriptome cell lines inherent in tumors
VASIL TSANOV & HRISTO TSANOV
Sofia, 2024
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome
cell lines inherent in tumors
/ second supplemented edition /
Authors: Vasil Tsanov, Eng., Ph.D., Assoc. Professor & Hristo Tsanov, DM - publishers
second edition, Sofia 2024
ISBN: 978-619-91534-6-8
DOI: 10.5281/zenodo.13777292
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
3
Genesis 1:29
“And God said, Behold, I have given you
every herb bearing seed, which is upon the
face of all the earth, and every tree, in the
which is the fruit of a tree yielding seed; to
you it shall be for meat”
i
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Let the preferred version of reading this book be electronic.
Print something really urgent on your recycled paper and printer toner!
This book is constructed in a structure aimed at limiting animal testing in
laboratory and preclinical settings.
Only refurbished computers, tablets and smart devices were used in the
creation of this book. Good practices have also been applied to reduce
energy consumption. The goal is to prevent additional carbon load in the
world around us.
Full calculations are posted here*:
Tsanov, V., Tsanov, H. (2024). Interpretable prediction for anticancer sensitivity of glycoside amides
(Version 2) [Data set], Zenodo, DOI: 10.5281/zenodo.13777312
*- the information is constantly updated - choose the current version at the moment
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
5
ABSTRACT
This ATLAS presents in appended form the complete monographic study (Tsanov & Tsanov,
2023) on the subject. The idea is to bring the results out of the "heavier" didactic format required for the
scientific presentation and at the same time to systematize all the information needed for the subsequent
clinical research.
The present excerpt from monographic work seeks to introduce the possibility that oncological
diseases become chronic (like diabetes). The theoretical basis on which we refer is the fact that cancer
cells feed only on carbohydrates. In turn, there is evidence that some nitrile glycosides have anti-cancer
properties.
The study is divided into four parts presented in the form of goals.
Proceeding from the particular to the general, the fine molecular structure and all possible
biochemical reactions of Amygdalin are examined. By itself, it is highly toxic to the physiologically
active animal cell. Amygdalin has NO pronounced antitumor properties. In the first goal, he examines
precisely the acceptable form for admission. It is concluded that the active anticancer molecular form is
a stoichiometric mixture of the amide and carboxyl derivative of the nitrile glycoside.
The second goal is to study the exact action of the anti-tumor product already introduced. After an
extremely precise biochemical and mathematical analysis, a series of biochemical cycles of the exact
passage of the product through the digestive system, penetration into the blood, approach to cancer cells
and selective passage through their cell membrane have been deduced.
The third goal is to define the chemical and pharmaceutical molecular forms. 54 methodological
and/or pharmaceutical models with hundreds of variables for each are reviewed and analyzed here.
The fourth goal (it is this purpose that is separately brought out in this edition) presents the
interpretable prediction of anticancer susceptibility of glycosidic amides. The affinities of the
pharmaceutical form to each known cancer cell line are reviewed. The results surpass many times all
anti-cancer drugs and with significantly reduced toxicity.
In an additional part, a generalized clinical control is presented. When conducting the treatment,
it is also vitally important to not divert the therapy process to irreversible pathology.
Result: The cancer can become chronic and become a practically curable disease.
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
6
ABBREVIATIONS USED IN THE TEXT
AACF
Active Anticancer Cell molecules Forms
AAF
Active apoptotic forms
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
7
CONTENT
ABSTRACT .............................................................................................................................................. 5
ABBREVIATIONS USED IN THE TEXT .............................................................................................. 6
CONTENT ................................................................................................................................................ 7
INTRODUCTION .................................................................................................................................... 9
STRUCTURAL METHODOLOGY ........................................................................................................ 9
Conducting the experiment ................................................................................................................... 9
Input data: ........................................................................................................................................... 10
Selection of testing algorithms:........................................................................................................... 27
Applicability of results ........................................................................................................................ 27
Presentation of results ......................................................................................................................... 28
RESULTS AND INTERPRETATION ................................................................................................... 28
Toxication of the cancer cell ............................................................................................................... 28
Determination of the drug dose ........................................................................................................... 33
FINAL REZULTS .................................................................................................................................. 37
Aerodigestive tract (Tractus aerodigestivus) ...................................................................................... 38
Autonomic ganglion (Ganglion autonomicum) .................................................................................. 41
Biliary tract (Ductus biliaris) .............................................................................................................. 43
Bone (Anatomia ossis) ........................................................................................................................ 44
Breast (Mamma) .................................................................................................................................. 47
Central nervous system (Systema nervosum centrale) ........................................................................ 51
Digestive system (Apparatus digestorius) .......................................................................................... 54
Endometrium (Endometrium) ............................................................................................................. 56
Hematopoietic and lymphoid tissues (Haematopoeticarum lymphoidearumque) .............................. 58
Kidney (Ren) ....................................................................................................................................... 64
Large intestine (Intestinum crassum) .................................................................................................. 67
Leukemia (Leuchaemia) ..................................................................................................................... 71
Liver (Hepar) ...................................................................................................................................... 74
Lung (Pulmo) ...................................................................................................................................... 76
Lymphoma (Lymphoma) ..................................................................................................................... 87
Myeloma (Myeloma) ........................................................................................................................... 90
Neuroblastoma (Neuroblastoma) ........................................................................................................ 92
Nervous system (Systema nervosum) .................................................................................................. 94
Oesophagus (Oesophagus) .................................................................................................................. 97
Ovary (Ovarium) ................................................................................................................................. 99
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
8
Pancreas (Pancreas) .......................................................................................................................... 101
Pleura (Pleurae) ................................................................................................................................ 104
Prostate (Prostata) ............................................................................................................................ 105
Salivary gland (Glandulae salivariae oris) ....................................................................................... 106
Skin (Cutis) ....................................................................................................................................... 107
Small intestine (Intestinum tenue)..................................................................................................... 111
Soft tissue (Mollis textus) .................................................................................................................. 112
Stomach (Stomachus) ........................................................................................................................ 114
Thyroid (Glandula thyreoidea) ......................................................................................................... 116
Upper aerodigestive tract (Tractus superior aerodigestive) ............................................................. 118
Urinary tract (Tractus urinarii) ......................................................................................................... 120
Urogenital system (Systema urogenitale) ......................................................................................... 122
RESULTS ANALYSIS ........................................................................................................................ 126
APPLYING THE RESULTS ................................................................................................................ 127
CLINICAL CONTROL ........................................................................................................................ 135
Correlation of bio constants .............................................................................................................. 135
Chemoprevention and Homeopathy.................................................................................................. 139
THE CONCLUSIONS OF THE PREVIOUS STUDIES ..................................................................... 140
On the first goal (Tsanov & Tsanov, 2020) .................................................................................. 140
The second goal (Tsanov & Tsanov, 2021) .................................................................................. 140
On the third goal (Tsanov & Tsanov, 2022) ................................................................................. 140
AUTHOR'S NOTES ............................................................................................................................. 141
ETHICS APPROVAL AND CONSENT TO PARTICIPATE............................................................. 142
HUMAN AND ANIMAL RIGHTS ..................................................................................................... 142
CONSENT FOR PUBLICATION ........................................................................................................ 142
AVAILABILITY OF DATA AND MATERIALS .............................................................................. 142
FUNDING ............................................................................................................................................. 142
CONFLICT OF INTEREST ................................................................................................................. 142
REFERENCES...................................................................................................................................... 143
CONTENTS OF FIGURES AND TABLES ........................................................................................ 144
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
9
INTRODUCTION
Assuming that some Active Anticancer Cell molecules Forms /AACF/ (secreted inside the cancer
cell) could be derived from several active pharmacological forms for oral administration (in combination
and/or separately) and their already considered druglikeness of the pharmaceutical form (GPCR ligand,
Ion channel modulator, Kinase inhibitor, Nuclear receptor ligand, Protease inhibitor, Enzyme inhibitor,
pharmacological and biological activity of oral active drugs (Lipinski's Rule, Ghose Filter and CMC-50-
Like Rule, Weber Filter, MDDR-Like Rule and BBB Likeness), QED (uwQED and wQED), non-
laboratory and no clinical information on the chemical (Receptor activity, Mutagenicity,
Carcinogenicity, Toxity), Lipophilicity, Water Solubility, Pharmacokinetics, Medical chemistry
indicators, etc., it is still not possible to get an idea of the influence of the studied molecules on the real
cancer lines.
The main research challenge is to create a sufficiently adapted methodological scheme and at the
same time to maintain the general conservatism of good oncological medical practices.
The aim of the present study is to consider the possibility of enhancing the accuracy of predicting
the efficacy of the studied pharmacological oral forms using models using several different sources of
information, but based on empirical studies on cancer cell lines.
- ◊ -
STRUCTURAL METHODOLOGY
Conducting the experiment
The current methodological program relies on a comparative analysis of non-identical variables.
In one case it values the IC50, and in the other pharmacokinetic and druglikeness indicators of potential
oral dosage forms.
In order to minimize the dualism in the interpretation, conditionally postulate some of the allowable
values that would be reflected in the processing of a sample of data from the general population. They
are:
a) Work is carried out with a statistical accuracy of 5% (thus aiming to equate the correlation of
some of the indicators due to stereoisomerism). In cases where there is a functional dependence of values
with different statistical accuracy, the one with the highest deviation is considered final;
b) To check the repeatability of the analysis (for each individual indicator), a minimum of 5
calculations are performed according to absolutely identical methodologies. If necessary, the tests are
performed until a mean deviation of not more than 1.10
-2
is obtained;
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
10
c) Some methodologies also require the definition of physical conditions; therefore, the following
are accepted as inputs: temperature (T) = 310K, pH
oral cavity
> 6.5÷7.5; pH
stomach
= 0.9 ÷ 3.1. Time is not a
factor - it is analyzed separately.
Input data:
Let us divide the amide/carboxylic derivatives of natural nitrile glycosides conditionally (Tabl.1)
into 64 groups, coinciding with the active anti-cancer molecular forms (AACF).
The input data represent the molecular structural properties themselves. With the exception of 9
molecules, the test substances do not have CAS numbers (Dimitrov, et al., 2016) (Yordanova, et al.,
2019). In order to achieve maximum repeatability of the results, all analyzes are performed from virtually
created images.
The working file formats (§III.1, Tsanov & Tsanov, 2023) used are *.cdx and *.c3xml. Standard
SMILE script generation followed. Each molecular record is of the "canonical SMILES" type. Some of
the isomeric forms are excluded here. Therefore, for each molecule is generated, etc. "isomeric
SMILES". The data from the latter will be corrective for causes in the interpretation of the results.
Table 1 Active pharmaceutical forms for oral use and their corresponding active anti-cancer
molecules obtained after passage through the cell membrane, based on hydrolyzed amide/carboxylic
acid derivatives of natural nitrile glycosides
login
number
active pharmaceutical forms for oral use
active anti-cancer molecular form obtained after
passage through the cell membrane
1.
A
B
C
D.
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
12
B
C
3.
4.
A.
B.
C.
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
14
8.
9.
10.
11.
12.
13.
14.
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
16
21.
22.
23.
А
B.
24.
25.
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
18
C.
D.
30.
31.
A.
B.
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
20
36.
37.
38.
39.
40.
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
22
D.
E.
F.
G.
H.
46.
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
24
52.
53.
A.
B.
54.
55.
56.
A.
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
26
60.
61.
A.
B.
62.
A.
B.
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
27
63.
64.
Selection of testing algorithms:
This part of the methodology is implemented through the web-based PaccMann™ (Cadow, Born,
Manica, Oskooei, & Martínez, 2020) service. The training set uses data from Genomics of Drug
Sensitivity in Cancer (Soares, et al., 2013) (GDSC) and Cancer Cell Line Encyclopedia (Ghandi, Huang,
& Jané-Valbuena, 2019) (CCLE). The value reported here is IC50 in log(µmol). The algorithm proposed
by the researchers of PaccMann project gives for epistemic and aleatoric confidences (in absolute value)
in the range of 0.850÷0.985. This is a good framework for bioactive substances and it is not necessary
to anti-logarithm the value, but to analyze it directly within the limits: at IC50 [log(µmol)] <1.02 might
be accepted that the studied molecule has “medicinal properties”. The correction of 0.2 over the integer
1.0 comes from the statistical error of such calculations. Some of the values are negative numbers, i.e. it
could be assumed that the studied molecules will also have restorative clinical properties (Sebaugh,
2011) (Gary, Zhengyin, Wensheng, & Masucci, 2012).
Applicability of results
The structure of the analysis for an interpretable prognosis of susceptibility to active anti-cancer
molecular forms of transcriptome cell lines inherent in tumors considers only the described structural
relationships between the molecule and the corresponding cellular effect. PaccMann outputs individual
topological (and/or structural) fragments as active. The latter, in turn, can be in the amide and carboxylic
oral form and in the amide and carboxylic active form. On the other hand, only a part of the molecule
that is not functionally significant for the process can be described. Last but not least, it should be taken
into account that the concentration of the amide pharmaceutical form is 4.87 times higher than the
carboxylic form, and even after the passage of the cell membrane of the cancer cell (only the amide
form) carboxylic is obtained, which maybe it with anti-cancer activity.
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
28
After several mathematical
1
and stoichiometric operations of the case, the values subjected to
comparative analysis acquire the following functional dependence:
where:
is the IC50 activity to be analyzed;
- value of the IC50 analysis for the amide
pharmacological form;
- value of the carboxylic pharmacological form;
- value from
the IC50 analysis for the active amide form and
- value from the IC50 analysis for the active
carboxylic form.
Applying the permissible values (§III.3.4, Tsanov & Tsanov, 2023) it follows that the maximum
value for IC50 must be less than 7.35 (with statistical accuracy included).
Presentation of results
All final values are presented in tabular form, using a “heat map” - without placing the numerical
values themselves. The color identification is as follows: dark green (#00B050) - negative values /best
effect/, light green (#92D050) - values from 0 to 2, dark blue (#0070C0) - 2.01 ÷ 4.00, light blue
(#00B0F0) - 4.01 ÷ 6.00 and orange (#FFC000) - 6.01 ÷ 7.35. Unstained cells do not necessarily mean
that there is no activity. The values of some of them could be in a similar order to those accepted in the
analysis. However, further research and individual assessments of each individual variable in the
comparison process are needed.
The two different input information flows (§III.3.4., Tsanov & Tsanov, 2023) and their differences
in the analysis of data collection and packaging, determines the fact that some pairs of cell lines will get
different results. That is why both possibilities are presented. They are interpreted together.
- ◊ -
RESULTS AND INTERPRETATION
Toxication of the cancer cell
Active apoptotic form (AAF) with manifested anticancer activity is formed according to their
molecular structure. For diglycoside compounds (Amygdalin / Gentiobiose / Lucumin / Primeverose /
Vicianin / Vicianose, etc.) primary enzymatic hydrolysis (gluconases - which are abundant in tissue
fluids) of the glycosidic bonds between the individual sugars takes place. The relationship between the
secondary carbohydrate and the reaction-determining group is stronger and requires a longer reaction
time and/or a specific enzyme such as amygdalin beta-gluconase. The latter is synthesized mainly inside
the cell itself. This leads us to conclude that the passage through the cell membrane of the cancer cell
1
No logarithmic conversion is performed, only the baseline numerical values of the IC50 analysis.
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
29
(§IV.2.1-2, Tsanov & Tsanov, 2023) occurs with only one carbohydrate molecule. Once inside the cell,
the only glycosidic bond is broken. This is how the AAFs themselves are created. Some of them are
listed in Tabl. 2.
Table 2 Active apoptotic amide/carboxylic acid molecular forms, based on hydrolyzed
amide/carboxylic acid derivatives of natural nitrile glycosides
chemical formula
name
natural precursor
(R)-2-hydroxy-2-phenylacetamide
Prunasin
Amygdalin
Lucumin
Vicianin
Sambunigrin
(R)-2-hydroxy-2-phenylacetic acid
(R)-2-hydroxy-2-(4-hydroxyphenyl)acetamide
Dhurrin
Taxiphyllein
Proteacin
p-Glucosyloxymendelo-
nitrile
(R)-2-hydroxy-2-(4-hydroxyphenyl)acetic
acid
(R)-2-hydroxy-2-(3-hydroxyphenyl)acetamide
Zierin
(R)-2-hydroxy-2-(3-hydroxyphenyl)acetic
acid
2-hydroxy-2-methylpropanamide
Linamarin
2-hydroxy-2-methylpropanoic acid
(S)-2-hydroxy-2-methylbutanamide
Lotaustralin
(S)-2-hydroxy-2-methylbutanoic acid
2-hydroxy-3-methylbut-2-enamide
Acacipetalin
2-hydroxy-3-methylbut-2-enoic acid
(2Z,4E)-4-(2-amino-1-hydroxy-2-
oxoethylidene)hex-2-enedioic acid
Triglochinin
(2E,4Z)-3-(carboxymethyl)-2-hydroxyhexa-
2,4-dienedioic acid
(S)-1-hydroxycyclopent-2-ene-1-carboxamide
Deidaclin
Tetraphyllin A
(S)-1-hydroxycyclopent-2-ene-1-carboxylic
acid
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
30
(1S,4S)-1,4-dihydroxycyclopent-2-ene-1-
carboxamide
Tetraphyllin B
Volkenin
Taraktophyllin
(1S,4S)-1,4-dihydroxycyclopent-2-ene-1-
carboxylic acid
(1R,4R)-1,4,5-trihydroxycyclopent-2-ene-1-
carboxamide
Gynocardin
(1R,4R)-1,4,5-trihydroxycyclopent-2-ene-1-
carboxylic acid
(Z)-2-((4S,6R)-4,6-dihydroxycyclohex-2-en-
1-ylidene)acetamide
Menisdaurin
(Z)-2-((4S,6R)-4,6-dihydroxycyclohex-2-en-
1-ylidene)acetic acid
(R)-2-hydroxy-3-methylbutanamide
Volkenin
(R)-2-hydroxy-3-methylbutanoic acid
(E)-2-((4S,5R,6R)-4,5,6-trihydroxycyclohex-
2-en-1-ylidene)acetamide
Griffonin
(E)-2-((4S,5R,6R)-4,5,6-trihydroxycyclohex-
2-en-1-ylidene)acetic acid
(Z)-2-((4R,5R,6S)-5,6-dihydroxy-4-
methoxycyclohex-2-en-1-ylidene)acetamide
Bauhinin
(Z)-2-((4R,5R,6S)-5,6-dihydroxy-4-
methoxycyclohex-2-en-1-ylidene)acetic acid
(E)-2-((4R,6S)-4,6-dihydroxycyclohex-2-en-
1-ylidene)acetamide
Purshianin
(E)-2-((4R,6S)-4,6-dihydroxycyclohex-2-en-
1-ylidene)acetic acid
(E)-2-((4S,5R,6R)-4,5,6-trihydroxycyclohex-
2-en-1-ylidene)acetamide
Lithospermoside
(E)-2-((4S,5R,6R)-4,5,6-trihydroxycyclohex-
2-en-1-ylidene)acetic acid
(1R,2R,4R,6S,E)-3-(2-amino-2-
oxoethylidene)-2,4,6-trihydroxycyclohexyl
benzoate
Campyloside A
(E)-2-((2R,3R,4S,6R)-3-(benzoyloxy)-2,4,6-
trihydroxycyclohexylidene)acetic acid
(1S,2R,4R,6S,E)-3-(2-amino-2-
oxoethylidene)-6-(benzoyloxy)-2,4-
dihydroxycyclohexyl 1H-pyrrole-2-
carboxylicate
Campyloside B
(E)-2-((2R,3S,4S,6R)-3-((1H-pyrrole-2-
carbonyl)oxy)-4-(benzoyloxy)-2,6-
dihydroxycyclohexylidene)acetic acid
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
31
(2S,3S)-2,3-dihydroxy-4-methoxy-1-methyl-
6-oxo-1,2,3,6-tetrahydropyridine-3-
carboxamide
Acalyphin
(2S,3S)-2,3-dihydroxy-4-methoxy-1-methyl-
6-oxo-1,2,3,6-tetrahydropyridine-3-carboxylic
acid
4-hydroxy-3-(hydroxymethyl)but-2-enamide
Sutherlandin
4-hydroxy-3-(hydroxymethyl)but-2-enoic acid
(Z)-4-hydroxy-2-methylbut-2-enamide
Rhodiocyanoside A
(Z)-4-hydroxy-2-methylbut-2-enoic acid
(Z)-2-(hydroxymethyl)but-2-enamide
Rhodiocyanoside D
(Z)-2-(hydroxymethyl)but-2-enoic acid
(2R,3R)-2,3-bis(hydroxymethyl)oxirane-2-
carboxamide
Sarmentosin epoxide
(2R,3R)-2,3-bis(hydroxymethyl)oxirane-2-
carboxylic acid
(S)-2-hydroxy-3-(hydroxymethyl)but-3-
enamide
Cardiospermin
(S)-2-hydroxy-3-(hydroxymethyl)but-3-enoic
acid
(S)-4-amino-3-hydroxy-2-methylene-4-
oxobutyl 4-hydroxybenzoate
Cardiospermin p-
hydrosybenzoate
(S)-2-hydroxy-3-(((4-
hydroxybenzoyl)oxy)methyl)but-3-enoic acid
(S)-4-amino-3-hydroxy-2-methylene-4-
oxobutyl sulfate
Cardiospermin sulfate
(S)-2-(carboxy(hydroxy)methyl)allyl sulfate
(1R,4R)-4-carbamoyl-4-hydroxycyclopent-2-
en-1-yl sulfate
Tetraphylin B sulphate
(Epitetraphylin B sulfate)
(1R,4R)-4-carboxy-4-hydroxycyclopent-2-en-
1-yl sulfate
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
32
(1R,2R,4S,5R)-2,4-dihydroxy-6-
oxabicyclo[3.1.0]hexane-2-carboxamide
Passisuberosin
(Epipassisuberosin)
(1R,2R,4S,5R)-2,4-dihydroxy-6-
oxabicyclo[3.1.0]hexane-2-carboxylic acid
(2S,3R)-2,3-dihydroxy-4-methoxy-1-methyl-
6-oxo-1,2,3,6-tetrahydropyridine-3-
carboxamide
Acalyphin
(2S,3R)-2,3-dihydroxy-4-methoxy-1-methyl-
6-oxo-1,2,3,6-tetrahydropyridine-3-carboxylic
acid
(R)-2-hydroxy-2-(4-
isopropylphenyl)acetamide
p-isopropylmandelonitrile
glucose
(R)-2-hydroxy-2-(4-isopropylphenyl)acetic
acid
Each of these molecules alone would not cross the cell membrane of the cancer cell. Only those
related to carbohydrate and fulfilling the conditions of (§IV.2.1-2, Tsanov & Tsanov, 2023) will block
and/or permanently damage her normal physiology. The use of AAF (Tabl. 2) directly for treatment will
lead to severe toxic and allergic responses of the body.
By themselves, these compounds or their homologues are still used in conservative chemotherapy
(Chabner & Longo, 2018) (Airley, 2009) (Priestman, 2012). Glycosides such as Rehmapicroside,
Loganic acid, HMBOA D-glucoside, Glucose beta-1,3-isofagamine, Vanillyl beta-D-glucopyranoside
and others. Although they contain AAF of the proposed type, they would not cross the cell membrane
of the cancer cell. They do not fulfill the condition of (§IV.2.2., Tsanov & Tsanov, 2023), in the part of
the amide derivative which is to be hydrolyzed by a transitional complex with a carboxylic acid.
The relative inertness of the glycosidic bond (in vivo) also allows the use of different amide-
carboxylic glycosides simultaneously. This is also observed in nature with regard to the distribution of
nitrile glycosides - they are often more than one representative in one plant. Thus, different AAFs can
be injected simultaneously, at different concentrations and at different times, in order to closely
differentiate the different types of cancers, through the synergistic action of the controlled toxicity itself
inside the "attacked" cell.
Natural nitrile glycosides would not cross the cancer cell membrane. They decompose to HCN-
acid, phenyl methanol and carbohydrate. They do NOT have anticancer activity due to their inability to
reach the target unchanged. These compounds, in their natural form, are extremely toxic to the human
body. Their application is not a treatment, even in a higher concentration they cause irreversible
pathology over the physiologically active animal cell. Dozens of their modified forms have been
theoretically derived, but their amides and their carboxylic acids are the most promising for their
introduction into conservative oncology. The fact is that the cancer cell itself tries to counteract it in a
fairly certain way.
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
33
Determination of the drug dose
The drug dose is determined by considering all possible substances obtained by the final hydrolysis
of the glycosidic bond inside the cancer cell (Tabl. 2 & 3).
Table 3 Nature and concentration of active anticancer cell molecules obtained after crossing the cell
membrane by their natural precursors
AACF chemical formula
obtained after crossing the
cell membrane
natural precursor enzymatically
modified to amide and carboxylic acid
AACF concentration derived
from 1 mg/ml pharmacological
form
[ mg/ml ]
Prunasin 4.87:1
Amygdalin 4.87:1
Lucumin 4.87:1
Vicianin 4.87:1
Sambunigrin 4.87:1
0.40
0.27
0.27
0.27
0.40
Dhurrin 4.87:1
Taxiphyllin 4.87:1
Proteacin 4.87:1
p-Glucosyloxymandelonitrile 4.87:1
0.42
0.42
0.31
0.42
Zierin 4.87:1
0.42
Linamarin 4.87:1
0.32
Lotaustralin 4.87:1
0.35
Acacipetalin 4.87:1
0.34
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
34
Triglochinin 4.87:1
0.47
Deidaclin 4.87:1
Tetraphyllin A 4.87:1
0.36
0.36
Tetraphyllin B 4.87:1
Volkenin 4.87:1
Taraktophyllin 4.87:1
0.39
0.39
0.39
Gynocardin 4.87:1
0.41
Menisdaurin 4.87:1
0.42
Epiheterodendrin 4.87:1
0.35
Griffonin 4.87:1
0.44
Bauhinin 4.87:1
0.46
Purshianin 4.87:1
0.42
Lithospermoside 4.87:1
0.44
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
36
Cardiospermin 4.87:1
0.45
Cardiospermin p-hydrosybenzoate 4.87:1
0.61
Cardiospermin sulfate 4.87:1
0.56
Tetraphylin B sulphate
(Epitetraphylin B sulfate) 4.87:1
0.59
0.42
Passisuberosin
(Epipassisuberosin) 4.87:1
0.50
0.34
Acalyphin 4.87:1
0.57
p-isopropylmandelonitrile glucose 4.87:1
0.54
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
37
The use of two or more pharmaceutical forms would not prevent their penetration subject to the
mass ratios between the active antitumor amide and the active carboxylic transfer form.
The chemical compounds listed in Tabl. 2 & 3 and are currently used as: anti-migrane, anti-
atherosclerotic, anticoagulant, treatment of HIV, anti-cancer, anti-asthmatic, anti-hypertensive, anti-
epileptic, analgesic, ocular anti-inflammatory, anti-hypertensive, hypnotic, anesthetic, anti-allergic,
aromatase inhibitor, anti-ulcerative, anti-neoplastic, antibacterial, anticoccidial, contraceptive, tyrosine-
kinase inhibitor treatment of mast cell tumors, etc.. The difference is that with the proposed technology
they are formed inside the cell itself and thus minimize their overall toxicity in the body.
- ◊ -
FINAL REZULTS
The analysis and subsequent presentation of the results was conducted according to §III.3.4, Tsanov &
Tsanov, 2023:
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Aerodigestive tract (Tractus aerodigestivus)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Aerodigestive tract (Tabl.4.1. a. & b.), it is concluded that:
- main potential medicines are: AACF 4.C., 5.C., 5.D., 19., 23.A., 40., 56.B. and 63.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.C., 5.A., 31.B., 34., 51.A., 56.A. and 57.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.1. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Aerodigestive tract: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
carcinoma
A-253
BB30-HNC
BB49-HNC
BHY
BICR-10
BICR-22
BICR-31
BICR-78
Ca9-22
CAL-27
CAL-33
COLO-680N
Detroit-562
EC-GI-10
ESO-26
ESO-51
FADU
FLO-1
H-3118
HCE-4
HN
HO-1-N-1
HO-1-u-1
HSC-2
HSC-3
HSC-4
JHU-011
JHU-022
JHU-029
KON
KOSC-2
KYAE-1
KYSE-140
KYSE-150
KYSE-180
KYSE-220
KYSE-270
KYSE-410
KYSE-450
KYSE-50
KYSE-510
KYSE-520
KYSE-70
LB771-HNC
OACM5-1
OACp-4C
OE-19
OE-21
OSC-19
OSC-20
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
39
PCI-15A
PCI-30
PCI-38
PCI-4B
PCI-6A
PE/CA-PJ15
RPMI-2650
SAS
SAT
SCC-15
SCC-25
SCC-4
SCC-9
SCC-90
SK-GT-4
SKN-3
TE-1
TE-10
TE-11
TE-12
TE-15
TE-4
TE-5
TE-6
TE-8
TE-9
T-T
other
DOK
OE-33
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948730.v1
Table 4.1. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Aerodigestive tract: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
carcinoma
A-253
BB30-HNC
BB49-HNC
BHY
BICR-10
BICR-22
BICR-31
BICR-78
Ca9-22
CAL-27
CAL-33
COLO-680N
Detroit-562
EC-GI-10
ESO-26
ESO-51
FADU
FLO-1
H-3118
HCE-4
HN
HO-1-N-1
HO-1-u-1
HSC-2
HSC-3
HSC-4
JHU-011
JHU-022
JHU-029
KON
KOSC-2
KYAE-1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
40
KYSE-140
KYSE-150
KYSE-180
KYSE-220
KYSE-270
KYSE-410
KYSE-450
KYSE-50
KYSE-510
KYSE-520
KYSE-70
LB771-HNC
OACM5-1
OACp-4C
OE-19
OE-21
OSC-19
OSC-20
PCI-15A
PCI-30
PCI-38
PCI-4B
PCI-6A
PE/CA-PJ15
RPMI-2650
SAS
SAT
SCC-15
SCC-25
SCC-4
SCC-9
SCC-90
SK-GT-4
SKN-3
TE-1
TE-10
TE-11
TE-12
TE-15
TE-4
TE-5
TE-6
TE-8
TE-9
T-T
other
DOK
OE-33
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948730.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
41
Autonomic ganglion (Ganglion autonomicum)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Autonomic ganglion (Tabl.4.2. а. & b.), it is concluded that:
- main potential medicines are: AACF 1.B., 1.C., 4.C., 5.C., 5.D., 19., 23.A., 31.B., 31.C., 39., 40., 45.E., 51.A., 51.B., 56.A., 56.B., 57., 61.A., 61.B., 63. and 64.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.A., 1.D., 1.H., 4.A., 4.B., 5.A., 5.B., 7., 9., 11., 12., 14., 25., 30., 31.A., 32., 33., 36., 37., 38., 41., 42., 43., 44., 45.B., 45.H., 46., 47., 48., 49., 50.,
52., 55., 58., 59., 60. and 62.B.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.2. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Autonomic ganglion: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
G
H
I
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
neuroblastoma
KELLY
NB-1
SIMA
other
CHP-126
CHP-212
IMR-32
KP-N-RT-BM-1
KP-N-SI9s
KP-N-YN
MHH-NB-11
NH-6
SH-SY5Y
SK-N-AS
SK-N-BE-2
SK-N-DZ
SK-N-FI
SK-N-SH
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948727.v1
Table 4.2. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Autonomic ganglion: Part 2
active anti-cancer molecular forms
cell lines
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
neuroblastoma
KELLY
NB-1
SIMA
other
CHP-126
CHP-212
IMR-32
KP-N-RT-BM-1
KP-N-SI9s
KP-N-YN
MHH-NB-11
NH-6
SH-SY5Y
SK-N-AS
SK-N-BE-2
SK-N-DZ
SK-N-FI
SK-N-SH
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948727.v1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
42
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
43
Biliary tract (Ductus biliaris)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Biliary tract (Tabl.4.3. a. & b.), it is concluded that:
- main potential medicines are: AACF 5.A., 5.C., 12., 19., 23.A., 34., 40., 45.E., 51.A., 56.A., 56.B., 61.B. and 63.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.B., 1.C., 1.D., 4.A., 4.B., 4.C., 5.B., 5.D., 30., 31.A., 31.B., 32., 33., 36., 42., 44., 45.B., 48., 49., 51.B., 52., 55., 57., 58., 60., 61.A., 62.B. and 64.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.3. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Biliary tract: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
other
HuCC-T1
HuH-28
SNU-1079
SNU-1196
SNU-245
SNU-308
SNU-478
SNU-869
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948724.v1
Table 4.3. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Biliary tract: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
other
HuCC-T1
HuH-28
SNU-1079
SNU-1196
SNU-245
SNU-308
SNU-478
SNU-869
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948724.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
44
Bone (Anatomia ossis)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Bone (Tabl.4.4. а. & b.), it is concluded that:
- main potential medicines are: AACF 4.C., 5.C., 5.D., 19., 40., 56.B. and 63.;
- duplication of treatment and / or substitution on medical grounds: AACF 23.A., 31.B., 45.E. and 56.A.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.4. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Bone: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
G
H
I
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
chondrosarcoma
CAL-78
CAL-78*
CHSA-0011
CHSA-0108
CHSA-8926
H-EMC-SS
Ewings sarcoma-peripheral primitive neuroectodermal tumour
A-673
CADO-ES1
CADO-ES1*
ES-1
ES-3
ES-4
ES-5
ES-6
ES-7
ES-8
EW-1
EW-11
EW-12
EW-13
EW-16
EW-18
EW-22
EW-24
EW-3
EW-7
SK-ES-1
SK-ES-1*
SK-PN-DW
TC-71
TC-71*
osteosarcoma
CAL-72
G-292, clone A141B1
G-292, clone A141B1*
HOS
HOS*
HuO-3N1
HuO-9
MG-63
MG-63*
NOS-1
NY
Saos-2
Saos-2*
U-2-OS
other
143B
CS-1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
45
EW-8
EWS-502
HS-706.T
HS-737.T
HS-819.T
HS-821.T
HS-822.T
HS-863.T
HS-870.T
HS-888.T
MHH-ES-1
OUMS-27
RD-ES
SJSA-1
SJSA-1*
SK-N-MC
SW-1353
T-173
TC-32
U-2-OS
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948721.v1
Table 4.4. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Bone: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
chondrosarcoma
CAL-78
CAL-78*
CHSA-0011
CHSA-0108
CHSA-8926
H-EMC-SS
Ewings sarcoma-peripheral primitive neuroectodermal tumour
A-673
CADO-ES1
CADO-ES1*
ES-1
ES-3
ES-4
ES-5
ES-6
ES-7
ES-8
EW-1
EW-11
EW-12
EW-13
EW-16
EW-18
EW-22
EW-24
EW-3
EW-7
SK-ES-1
SK-ES-1*
SK-PN-DW
TC-71
TC-71*
osteosarcoma
CAL-72
G-292 clone A141B1
G-292 clone A141B1*
HOS
HOS*
HuO-3N1
HuO-9
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
46
MG-63
MG-63*
NOS-1
NY
Saos-2
Saos-2*
U-2-OS
other
CAL-72
G-292, clone A141B1
G-292, clone A141B1*
HOS
HOS*
HuO-3N1
HuO-9
MG-63
MG-63*
NOS-1
NY
U-2-OS
other
143B
CS-1
EW-8
EWS-502
HS-706.T
HS-737.T
HS-819.T
HS-821.T
HS-822.T
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948721.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
47
Breast (Mamma)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Breast (Tabl.4.5. a. & b.), it is concluded that:
- main potential medicines are: AACF 4.C., 5.C., 5.D., 19., 23.A., 31.B., 40., 48., 51.A., 56.A., 56.B. and 63.;
- duplication of treatment and / or substitution on medical grounds: AACF 5.A., 34., 39., 45.E., 46., 51.B., 57., 61.A., 61.B. and 62.B.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.5. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Breast: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
carcinoma
AU-565
AU-565*
BT-20
BT-20*
BT-474
BT-474*
BT-483
BT-483*
BT-549
BT-549*
CAL-120
CAL-120*
CAL-148
CAL-148*
CAL-51
CAL-51*
CAL-851
CAL-851*
CAMA-1
CAMA-1*
COLO-824
COLO-824*
DU-4475
EFM-19
EFM-19*
EFM-192A
EFM-192A*
EVSA-T
EVSA-T*
HCC-1143
HCC-1143*
HCC-1187
HCC-1187*
HCC-1395
HCC-1395*
HCC-1419
HCC-1419*
HCC-1428
HCC-1428*
HCC-1500
HCC-1500*
HCC-1569
HCC-1569*
HCC-1599
HCC-1599*
HCC-1806
HCC-1806*
HCC-1937
HCC-1937*
HCC-1954
HCC-1954*
HCC-202
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
48
HCC-202*
HCC-2157
HCC-2157*
HCC-2218
HCC-2218*
HCC-38
HCC-38*
HCC-70
HCC-70*
HDQ-P1
HDQ-P1*
Hs-578T
Hs-578T*
JIMT-1
JIMT-1*
MCF-7
MCF-7*
MDA-MB-157
MDA-MB-157*
MDA-MB-231
MDA-MB-231*
MDA-MB-330
MDA-MB-361
MDA-MB-361*
MDA-MB-415
MDA-MB-415*
MDA-MB-436
MDA-MB-436*
MDA-MB-453
MDA-MB-453*
MDA-MB-468
MDA-MB-468*
MFM-223
MRK-nu-1
OCUB-M
T-47D
T-47D*
UACC-812
UACC-812*
UACC-893
UACC-893*
ZR-75-30
ZR-75-30*
other
HMC-1-8
HMEL
HS-274.T
HS-281.T
HS-343.T
HS-606.T
HS-739.T
HS-742.T
KPL-1
MDA-MB-134-VI
MDA-MB-175-VII
SK-BR-3
YMB-1
ZR-75-1
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948718.v1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
49
Table 4.5. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Breast: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
carcinoma
AU-565
AU-565*
BT-20
BT-20*
BT-474
BT-474*
BT-483
BT-483*
BT-549
BT-549*
CAL-120
CAL-120*
CAL-148
CAL-148*
CAL-51
CAL-51*
CAL-851
CAL-851*
CAMA-1
CAMA-1*
COLO-824
COLO-824*
DU-4475
EFM-19
EFM-19*
EFM-192A
EFM-192A*
EVSA-T
EVSA-T*
HCC-1143
HCC-1143*
HCC-1187
HCC-1187*
HCC-1395
HCC-1395*
HCC-1419
HCC-1419*
HCC-1428
HCC-1428*
HCC-1500
HCC-1500*
HCC-1569
HCC-1569*
HCC-1599
HCC-1599*
HCC-1806
HCC-1806*
HCC-1937
HCC-1937*
HCC-1954
HCC-1954*
HCC-202
HCC-202*
HCC-2157
HCC-2157*
HCC-2218
HCC-2218*
HCC-38
HCC-38*
HCC-70
HCC-70*
HDQ-P1
HDQ-P1*
Hs-578T
Hs-578T*
JIMT-1
JIMT-1*
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
50
MCF-7
MCF-7*
MDA-MB-157
MDA-MB-157*
MDA-MB-231
MDA-MB-231*
MDA-MB-330
MDA-MB-361
MDA-MB-361*
MDA-MB-415
MDA-MB-415*
MDA-MB-436
MDA-MB-436*
MDA-MB-453
MDA-MB-453*
MDA-MB-468
MDA-MB-468*
MFM-223
MRK-nu-1
OCUB-M
T-47D
T-47D*
UACC-812
UACC-812*
UACC-893
UACC-893*
ZR-75-30
ZR-75-30*
other
HMC-1-8
HMEL
HS-274.T
HS-281.T
HS-343.T
HS-606.T
HS-739.T
HS-742.T
KPL-1
MDA-MB-134-VI
MDA-MB-175-VII
SK-BR-3
YMB-1
ZR-75-1
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948718.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
51
Central nervous system (Systema nervosum centrale)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Central nervous system (Tabl.4.6. a. & b.), it is concluded that:
- main potential medicines are: AACF 1.B., 1.C., 4.C., 5.A., 5.C., 5.D., 19., 23.A., 30., 31.B., 34., 39., 40., 45.E., 51.A., 51.B., 52., 56.A., 56.B., 57., 60., 61.A., 61.B., 63. and 64.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.D., 12., 25., 31.A., 31.C., 33., 37., 43., 44., 45.B., 46., 48., 49., 55., 58., 59. and 62.B.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.6. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Central nervous system: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
D
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
glioma
A-172
GaMG
H-4
SF-126
SF-295
SW-1088
SW-1783
T-98G
other
1321-N1
42-MG-BA
8-MG-BA
A-1207
AM-38
BECKER
CAS-1
CCF-STTG1
CH-157MN
D-283Med
D-341Med
Daoy
DBTRG-05MG
DK-MG
F-5
GB-1
GI-1
GMS-10
GOS-3
HS-683
IOMM-Lee
KALS-1
KG-1-C
KNS-42
KNS-60
KNS-81
KS-1
LN-18
LN-215
LN-229
LN-235
LN-319
LN-340
LN-382
LN-428
LN-443
LN-464
LN-Z308
M-059-K
MOG-G-CCM
MOG-G-UVW
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
52
NMC-G1
ONS-76
SF-172
SF-767
SNB-19
SNU-1105
SNU-201
SNU-466
SNU-489
SNU-626
SNU-738
TM-31
U-118-MG
U-138-MG
U-178
U-251-MG
U-343
U-87-MG
YH-13
YKG-1
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948715.v1
Table 4.6. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Central nervous system: Part 2
active anti-cancer molecular forms
cell lines
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
glioma
A-172
GAMG
H-4
SF-126
SF-295
SW-1088
SW-1783
T-98G
other
1321-N1
42-MG-BA
8-MG-BA
A-1207
AM-38
BECKER
CAS-1
CCF-STTG1
CH-157MN
D-283Med
D-341Med
Daoy
DBTRG-05MG
DK-MG
F-5
GB-1
GI-1
GMS-10
GOS-3
HS-683
IOMM-Lee
KALS-1
KG-1-C
KNS-42
KNS-60
KNS-81
KS-1
LN-18
LN-215
LN-229
LN-235
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
53
LN-319
LN-340
LN-382
LN-428
LN-443
LN-464
LN-Z308
M-059-K
MOG-G-CCM
MOG-G-UVW
NMC-G1
ONS-76
SF-172
SF-767
SNB-19
SNU-1105
SNU-201
SNU-466
SNU-489
SNU-626
SNU-738
TM-31
U-118-MG
U-138-MG
U-178
U-251-MG
U-343
U-87-MG
YH-13
YKG-1
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948715.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
54
Digestive system (Apparatus digestorius)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Digestive system (Tabl.4.7. a. & b.), it is concluded that:
- main potential medicines: AACF 4.C., 5.C., 19., 23.А., 31.B., 40., 56.B. and 63.;
- duplication of treatment and / or substitution on medical grounds: AACF 5.D., 20.B., 39., 56.A. and 57.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.7. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Digestive system: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
carcinoma
23132-87
AGS
C-3A
ECC-10
ECC-12
EGI-1
ETK-1
FU-97
GCIY
GT-3TKB
HGC-27
HLE
Hs-746T
HSC-39
HuCCT-1
HuH-1
HuH-7
HuTu-80
IM-95
JHH-1
JHH-6
JHH-7
KATO-III
MK-N1
MK-N28
MK-N45
MK-N7
NCI-N87
NCI-SNU1
NCI-SNU16
NCI-SNU5
NUGC-3
NUGC-4
OCUM-1
RERF-GC-1B
RF-48
SK-GT-2
SK-HEP-1
SNU-182
SNU-387
SNU-398
SNU-423
SNU-449
SNU-475
TGBC-11TKB
TGBC-1TKB
TGBC-24TKB
other
Hep 3B2 1-7
JHH-2
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
55
JHH-4
SCH
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948712.v1
Table 4.7. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Digestive system: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
carcinoma
23132-87
AGS
C-3A
ECC-10
ECC-12
EGI-1
ETK-1
FU-97
GCIY
GT-3TKB
HGC-27
HLE
Hs-746T
HSC-39
HuCCT-1
HuH-1
HuH-7
HuTu-80
IM-95
JHH-1
JHH-6
JHH-7
KATO-III
MK-N1
MK-N28
MK-N45
MK-N7
NCI-N87
NCI-SNU1
NCI-SNU16
NCI-SNU5
NUGC-3
NUGC-4
OCUM-1
RERF-GC-1B
RF-48
SK-GT-2
SK-HEP-1
SNU-182
SNU-387
SNU-398
SNU-423
SNU-449
SNU-475
TGBC-11TKB
TGBC-1TKB
TGBC-24TKB
other
Hep 3B2 1-7
JHH-2
JHH-4
SCH
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948712.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
56
Endometrium (Endometrium)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Endometrium (Tabl.4.8. a. & b.), it is concluded that:
- main potential medicines are: AACF 1.C., 4.C., 5.A., 5.C., 5.D., 19., 23.A., 30., 31.B., 31.C., 34., 36., 39., 40., 44., 45.B., 45.E., 46., 48., 49., 51.A., 51.B., 52., 56.A., 56.B., 57., 61.A., 61.B. and 63.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.D., 4.A., 4.B., 5.B., 7., 12., 25., 31.A., 32., 33., 37., 38., 47., 50., 55., 62.B. and 64.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.8. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Endometrium: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
carcinoma
EN
KLE
other
AN3-CA
COLO-684
EFE-184
ESS-1
HEC-108
HEC-151
HEC-1A
HEC-1B
HEC-251
HEC-265
HEC-50B
HEC-59
HEC-6
ISHIKAWAHeraklio-02-ER
JHUEM-1
JHUEM-2
JHUEM-3
MFE-280
MFE-296
MFE-319
RL95-2
SNG-M
SNU-1077
SNU-685
TEN
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948709.v1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
57
Table 4.8. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Endometrium: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
carcinoma
EN
KLE
other
AN3-CA
COLO-684
EFE-184
ESS-1
HEC-108
HEC-151
HEC-1A
HEC-1B
HEC-251
HEC-265
HEC-50B
HEC-59
HEC-6
ISHIKAWAHeraklio-02-ER
JHUEM-1
JHUEM-2
JHUEM-3
MFE-280
MFE-296
MFE-319
RL95-2
SNG-M
SNU-1077
SNU-685
TEN
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948709.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
58
Hematopoietic and lymphoid tissues (Haematopoeticarum lymphoidearumque)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Hematopoietic and lymphoid tissues (Tabl.4.9. a. & b.), it is concluded that:
- main potential medicines are: AACF 1.B., 1.C., 4.C., 5.A., 5.B., 5.C., 5.D., 7., 12., 19., 23.A., 25., 30., 31.A., 31.B., 31.C., 33., 34., 36., 37., 38., 39., 40., 42., 43., 44., 45.B., 45.E., 46., 47., 48., 49., 50., 51.A., 51.B., 52.,
56.A., 56.B., 57., 61.A., 61.B., 62.B., 63. and 64.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.D., 4.A., 4.B., 9., 11., 14., 32., 41., 45.H., 55., 59. and 60.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.9. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Hematopoietic and lymphoid tissues: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
haematopoietic neoplasm
CMK
HEL
KU-812
lymphoid neoplasm
697
CA-46
DB
DEL
EB-2
EHEB
EJM
HH
JM-1
Loucy
MC-116
MM-1S
NAMALWA
Reh
RL
ST-486
other
A3/Kawakami
A4/Fukuda
ALL-SIL
AML-193
AMO-1
BCP-1
BDCM
BL-41
BL-70
BV-173
CI-1
CMK-11-5
CMK-86
CML-T1
COLO-677
COLO-775
Daudi
DND-41
DoHH-2
EB-1
EM-2
EoL-1
F-36P
GA-10
GDM-1
Granta-519
HDLM-2
HD-MY-Z
HEL-92.1.7
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
59
HL-60
HPB-ALL
HS-604.T
HS-611.T
HS-616.T
HS-751.T
HT
HTK
HuNS-1
HuT-102
HuT-78
JeKo-1
JJN-3
JK-1
Jurkat
JURL-MK1
JVM-2
JVM-3
K-562
KARPAS-299
KARPAS-422
KARPAS-620
Kasumi-1
Kasumi-2
Kasumi-6
KCL-22
KE-37
KE-97
KG-1
KHM-1B
Ki-JK
KMH-2
KMM-1
KMS-11
KMS-12-BM
KMS-18
KMS-20
KMS-21-BM
KMS-26
KMS-27
KMS-28-BM
KMS-34
KO-52
KOPN-8
KYO-1
L-1236
L-363
L-428
L-540
LAMA-84
LP-1
M-07e
ME-1
MEC-1
MEC-2
MEG-01
MHH-CALL-2
MHH-CALL-3
MHH-CALL-4
Mino
MJ
MOLM-13
MOLM-16
MOLM-6
MOLP-2
MOLP-8
MOLT-13
MOLT-16
MOLT-4
MONO-MAC-1
MONO-MAC-6
MOTN-1
MUTZ-5
MV-4-11
NALM-1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
60
NALM-19
NALM-6
NB-4
NCIH-929
NCO-2
NOMO-1
NU-DHL-1
NU-DUL-1
OCI-AML-2
OCI-AML-3
OCI-AML-5
OCI-Ly-10
OCI-Ly-19
OCI-Ly-3
OCI-M1
OPM-2
P12-ICHIKAWA
P31/FUJ
P3HR-1
PCM-6
Peer
PF-382
Pfeiffer
PL-21
Raji
RCH-ACV
REC-1
Ri-1
RPMI-8226
RPMI-8402
RS4;11
SEM
SET-2
SIG-M5
SKM-1
SK-MM-2
SR-786
SU-DHL-1
SU-DHL-10
SU-DHL-4
SU-DHL-5
SU-DHL-6
SU-DHL-8
SUP-B15
SUP-HD1
SUP-M2
SUP-T1
SUP-T11
TALL-1
TF-1
THP-1
TO-175.T
Toledo
U-266-B1
U-937
UT-7
WSU-DLCL2
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948706.v1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
61
Table 4.9. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Hematopoietic and lymphoid tissues: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
haematopoietic neoplasm
CMK
HEL
KU-812
lymphoid neoplasm
697
CA-46
DB
DEL
EB-2
EHEB
EJM
HH
JM-1
Loucy
MC-116
MM-1S
NAMALWA
Reh
RL
ST-486
other
A3/Kawakami
A4/Fukuda
ALL-SIL
AML-193
AMO-1
BCP-1
BDCM
BL-41
BL-70
BV-173
CI-1
CMK-11-5
CMK-86
CML-T1
COLO-677
COLO-775
Daudi
DND-41
DoHH-2
EB-1
EM-2
EoL-1
F-36P
GA-10
GDM-1
Granta-519
HDLM-2
HD-MY-Z
HEL-92.1.7
HL-60
HPB-ALL
HS-604.T
HS-611.T
HS-616.T
HS-751.T
HT
HTK
HuNS-1
HuT-102
HuT-78
JeKo-1
JJN-3
JK-1
Jurkat
JURL-MK1
JVM-2
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
62
JVM-3
K-562
KARPAS-299
KARPAS-422
KARPAS-620
Kasumi-1
Kasumi-2
Kasumi-6
KCL-22
KE-37
KE-97
KG-1
KHM-1B
Ki-JK
KMH-2
KMM-1
KMS-11
KMS-12-BM
KMS-18
KMS-20
KMS-21-BM
KMS-26
KMS-27
KMS-28-BM
KMS-34
KO-52
KOPN-8
KYO-1
L-1236
L-363
L-428
L-540
LAMA-84
LP-1
M-07e
ME-1
MEC-1
MEC-2
MEG-01
MHH-CALL-2
MHH-CALL-3
MHH-CALL-4
Mino
MJ
MOLM-13
MOLM-16
MOLM-6
MOLP-2
MOLP-8
MOLT-13
MOLT-16
MOLT-4
MONO-MAC-1
MONO-MAC-6
MOTN-1
MUTZ-5
MV-4-11
NALM-1
NALM-19
NALM-6
NB-4
NCIH-929
NCO-2
NOMO-1
NU-DHL-1
NU-DUL-1
OCI-AML-2
OCI-AML-3
OCI-AML-5
OCI-Ly-10
OCI-Ly-19
OCI-Ly-3
OCI-M1
OPM-2
P12-ICHIKAWA
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
63
P31/FUJ
P3HR-1
PCM-6
Peer
PF-382
Pfeiffer
PL-21
Raji
RCH-ACV
REC-1
Ri-1
RPMI-8226
RPMI-8402
RS4;11
SEM
SET-2
SIG-M5
SKM-1
SK-MM-2
SR-786
SU-DHL-1
SU-DHL-10
SU-DHL-4
SU-DHL-5
SU-DHL-6
SU-DHL-8
SUP-B15
SUP-HD1
SUP-M2
SUP-T1
SUP-T11
TALL-1
TF-1
THP-1
TO-175.T
Toledo
U-266-B1
U-937
UT-7
WSU-DLCL2
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948706.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
64
Kidney (Ren)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Kidney (Tabl.4.10. a. & b.), it is concluded that:
- main potential medicines are: AACF 4.C., 5.C., 5.D., 9., 31.B., 34., 40., 51.A., 56.A., 56.B. and 60.;
- duplication of treatment and / or substitution on medical grounds: AACF 19., 23.A., 45.E., and 57.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.10. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Kidney: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
adrenal cortical carcinoma
SW-13
carcinoma
769-P
769-P*
786-O
786-O*
A-498
A-498*
A-704
A-704*
ACHN
ACHN*
BB65-RCC
BFTC-909
BFTC-909*
Caki-1
Caki-1*
CAL-54
HA7-RCC
KMRC-1
KMRC-1*
KMRC-20
KMRC-20*
LB1047-RCC
LB2241-RCC
LB996-RCC
NCC010
NCC021
OS-RC-2
OS-RC-2*
RCC-10RGB
RCC-10RGB*
RCC-AB
RCC-ER
RCC-FG2
RCC-JF
RCC-JW
RCC-MF
RXF-393
SN-12C
TK-10
UO-31
VMRC-RCZ
VMRC-RCZ*
rhabdoid tumour
G-401
other
Caki-2
CAL-54
HEK-TE
HK-2
KMRC-2
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
65
KMRC-3
RCC-4
SK-RC-20
SK-RC-31
SLR-20
SLR-21
SLR-23
SLR-24
SLR-25
SLR-26
SNU-1272
SNU-349
SW-156
TUHR-10TKB
TUHR-14TKB
TUHR-4TKB
UM-RC-2
UM-RC-6
UOK-101
VMRC-RCW
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948703.v1
Table 4.10. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Kidney: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
adrenal cortical carcinoma
SW-13
carcinoma
769-P
769-P*
786-O
786-O*
A-498
A-498*
A-704
A-704*
ACHN
ACHN*
BB65-RCC
BFTC-909
BFTC-909*
Caki-1
Caki-1*
CAL-54
HA7-RCC
KMRC-1
KMRC-1*
KMRC-20
KMRC-20*
LB1047-RCC
LB2241-RCC
LB996-RCC
NCC010
NCC021
OS-RC-2
OS-RC-2*
RCC-10RGB
RCC-10RGB*
RCC-AB
RCC-ER
RCC-FG2
RCC-JF
RCC-JW
RCC-MF
RXF-393
SN-12C
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
66
TK-10
UO-31
VMRC-RCZ
VMRC-RCZ*
rhabdoid tumour
G-401
other
Caki-2
CAL-54
HEK-TE
HK-2
KMRC-2
KMRC-3
RCC-4
SK-RC-20
SK-RC-31
SLR-20
SLR-21
SLR-23
SLR-24
SLR-25
SLR-26
SNU-1272
SNU-349
SW-156
TUHR-10TKB
TUHR-14TKB
TUHR-4TKB
UM-RC-2
UM-RC-6
UOK-101
VMRC-RCW
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948703.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
67
Large intestine (Intestinum crassum)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Large intestine (Tabl.4.11. a & b.), it is concluded that:
- main potential medicines are: AACF 4.C., 5.A., 5.C., 5.D., 19., 23.A., 31.B., 34., 40., 51.A., 56.A., 56.B. and 63.;
- duplication of treatment and/or substitution on medical grounds: AACF 1.C., 31.C., 39., 45.E., 48. and 57.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.11. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Large intestine: Part 1
active anti-cancer molecular forms
cell lines
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
carcinoma
C2BBe1
C2BBe1*
CaR-1
CCK-81
CCK-81*
CL-11
CL-11*
CL-34
CL-34*
CL-40
CL-40*
COLO-205
COLO-205*
COLO-320HSR
COLO-678
COLO-678*
CW-2
CW-2*
GP5d
HCC-2998
HCC-56
HCC-56*
HCT-116
HCT-116*
HCT-15
HCT-15*
HT-115
HT-115*
HT-29
HT-29*
HT-55
HT-55*
KM-12
KM-12*
LoVo
LoVo*
LS-1034
LS-1034*
LS-123
LS-123*
LS-180
LS-180*
LS-411N
LS-411N*
LS-513
LS-513*
MDST-8
MDST-8*
NCI-H630
NCI-H716
NCI-H716*
NCI-H747
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
68
NCI-H747*
RCM-1
RCM-1*
RKO
RKO*
SK-CO-1
SK-CO-1*
SNU-1040
SNU-1040*
SNU-175
SNU-175*
SNU-407
SNU-407*
SNU-61
SNU-61*
SNU-81
SNU-81*
SNU-C1
SNU-C1*
SNU-C2B
SNU-C5
SNU-C5*
SW-1116
SW-1116*
SW-1417
SW-1417*
SW-1463
SW-1463*
SW-48
SW-48*
SW-620
SW-620*
SW-837
SW-837*
SW-948
SW-948*
T-84
T-84*
other
CL-14
COLO-201
COLO-320
DLD-1
GP2d
HCT-8
Hs-255.T
Hs-675.T
Hs-698.T
NCI-H508
OUMS-23
SNU-1033
SNU-1197
SNU-283
SNU-503
SNU-C2A
SNU-C4
SW-403
SW-480
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948700.v1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
69
Table 4.11. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Large intestine: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
carcinoma
C2BBe1
C2BBe1*
CaR-1
CCK-81
CCK-81*
CL-11
CL-11*
CL-34
CL-34*
CL-40
CL-40*
COLO-205
COLO-205*
COLO-320HSR
COLO-678
COLO-678*
CW-2
CW-2*
GP5d
HCC-2998
HCC-56
HCC-56*
HCT-116
HCT-116*
HCT-15
HCT-15*
HT-115
HT-115*
HT-29
HT-29*
HT-55
HT-55*
KM-12
KM-12*
LoVo
LoVo*
LS-1034
LS-1034*
LS-123
LS-123*
LS-180
LS-180*
LS-411N
LS-411N*
LS-513
LS-513*
MDST-8
MDST-8*
NCI-H630
NCI-H716
NCI-H716*
NCI-H747
NCI-H747*
RCM-1
RCM-1*
RKO
RKO*
SK-CO-1
SK-CO-1*
SNU-1040
SNU-1040*
SNU-175
SNU-175*
SNU-407
SNU-407*
SNU-61
SNU-61*
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
70
SNU-81
SNU-81*
SNU-C1
SNU-C1*
SNU-C2B
SNU-C5
SNU-C5*
SW-1116
SW-1116*
SW-1417
SW-1417*
SW-1463
SW-1463*
SW-48
SW-48*
SW-620
SW-620*
SW-837
SW-837*
SW-948
SW-948*
T-84
T-84*
other
CL-14
COLO-201
COLO-320
DLD-1
GP2d
HCT-8
Hs-255.T
Hs-675.T
Hs-698.T
NCI-H508
OUMS-23
SNU-1033
SNU-1197
SNU-283
SNU-503
SNU-C2A
SNU-C4
SW-403
SW-480
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948700.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
71
Leukemia (Leuchaemia)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Leukemia (Tabl.4.12. a. & b.), it is concluded that:
- main potential medicines are: AACF 1.C., 4.C., 5.C., 5.D., 19., 23.A., 25., 30., 31.B., 31.C., 34., 36., 37., 38., 39., 40., 45.E., 46., 50., 56.A., 56.B. 57. and 63.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.D., 1.G., 4.A., 4.B., 5.A., 5.B., 7., 12., 31.A., 32., 33., 41., 42., 43., 44., 45.B., 47., 48., 49., 50., 51.A., 51.B., 60., 61.A., 61.B., 62.B. and 64.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.12. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Leukemia: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
haematopoietic neoplasm
BV-173
CESS
CMK
CML-T1
EM-2
EoL-1
GDM-1
HEL
HL-60
JURL-MK1
K-562
Kasumi-1
KCL-22
KG-1
KMOE-2
KU-812
KY-821
LAMA-84
ME-1
MEG-01
ML-2
MOLM-13
MOLM-16
MONO-MAC-6
MV-4-11
NB-4
NKM-1
NOMO-1
OCI-AML-2
OCI-AML-3
OCI-AML-5
OCI-M1
P31/FUJ
PL-21
QIMR-WIL
RPMI-8866
RS4;11
SIG-M5
SKM-1
THP-1
lymphoid neoplasm
697
ALL-PO
ALL-SIL
ATN-1
BALL-1
BE-13
CCRF-CEM
CTV-1
DND-41
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
72
GR-ST
HAL-01
HC-1
HH
Jurkat
Karpas-231
Karpas-45
KE-37
KOPN-8
LC4-1
Loucy
MHH-CALL-2
MHH-PREB-1
MLMA
MN-60
MOLT-13
MOLT-16
MOLT-4
Mo-T
NALM-6
P12-Ichikawa
P30/OHK
PF-382
RCH-ACV
Reh
ROS-50
RPMI-8402
SUP-B15
SUP-B8
SUP-T1
U-698-M
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948697.v1
Table 4.12. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Leukemia: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
haematopoietic neoplasm
BV-173
CESS
CMK
CML-T1
EM-2
EoL-1
GDM-1
HEL
HL-60
JURL-MK1
K-562
Kasumi-1
KCL-22
KG-1
KMOE-2
KU-812
KY-821
LAMA-84
ME-1
MEG-01
ML-2
MOLM-13
MOLM-16
MONO-MAC-6
MV-4-11
NB-4
NKM-1
NOMO-1
OCI-AML-2
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
73
OCI-AML-3
OCI-AML-5
OCI-M1
P31/FUJ
PL-21
QIMR-WIL
RPMI-8866
RS4;11
SIG-M5
SKM-1
THP-1
lymphoid neoplasm
697
ALL-PO
ALL-SIL
ATN-1
BALL-1
BE-13
CCRF-CEM
CTV-1
DND-41
GR-ST
HAL-01
HC-1
HH
Jurkat
Karpas-231
Karpas-45
KE-37
KOPN-8
LC4-1
Loucy
MHH-CALL-2
MHH-PREB-1
MLMA
MN-60
MOLT-13
MOLT-16
MOLT-4
Mo-T
NALM-6
P12-Ichikawa
P30/OHK
PF-382
RCH-ACV
Reh
ROS-50
RPMI-8402
SUP-B15
SUP-B8
SUP-T1
U-698-M
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948697.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
74
Liver (Hepar)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Liver (Tabl.4.13. a. & b.), it is concluded that:
- main potential medicines are: AACF 1.B., 1.C., 4.C., 5.A., 5.C., 5.D., 19., 23.A., 30., 31.A., 31.B., 31.C., 34., 36., 37., 39., 40., 45.E., 48., 51.A., 56.A., 56.B., 57., 61.A., 61.B. and 63.;
- duplication of treatment and / or substitution on medical grounds: AACF 4.A., 4.B., 5.B., 7., 12., 32., 33., 38., 42., 43., 44., 45.B., 46., 49., 51.B., 52., 55., 60., 62.B. and 64.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.13. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Liver: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
carcinoma
Hep-G2/C3A
HLE
other
PLC/PRF/5
Hep-3B2.1-7
Hep-G2
HLF
HuH-1
HuH-6
HuH-7
JHH-1
JHH-2
JHH-4
JHH-5
JHH-6
JHH-7
Li-7
NCI-H684
PLC/PRF/5
SK-HEP-1
SNU-182
SNU-387
SNU-398
SNU-423
SNU-449
SNU-475
SNU-761
SNU-878
SNU-886
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948694.v1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
75
Table 4.13. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Liver: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
carcinoma
Hep-G2/C3A
HLE
other
PLC/PRF/5
Hep-3B2.1-7
Hep-G2
HLF
HuH-1
HuH-6
HuH-7
JHH-1
JHH-2
JHH-4
JHH-5
JHH-6
JHH-7
Li-7
NCI-H684
PLC/PRF/5
SK-HEP-1
SNU-182
SNU-387
SNU-398
SNU-423
SNU-449
SNU-475
SNU-761
SNU-878
SNU-886
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948694.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
76
Lung (Pulmo)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Lung (Tabl.4.14. a & b.), it is concluded that:
- main potential medicines are: AACF 4.C., 5.C., 5.D., 19., 23.A., 31.B., 40., 51.A., 56.A., 56.B., 57. and 63.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.C., 5.A., 12., 31.C., 34., 39., 45.E. and 48.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.14. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Lung: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
carcinoid-endocrine_tumour
NCI-H835
UMC-11
carcinoma
201T
A-427
A-549
A-549*
ABC-1
ABC-1*
BEN
BEN*
CAL-12T
CAL-12T*
CAL-U3
CAL-U3*
CAL-U6
CAL-U6*
ChaGo-K-1
ChaGo-K-1*
COLO-668
COLO-668*
COR-L105
COR-L105*
COR-L23
COR-L23*
COR-L279
COR-L279*
COR-L303
COR-L311
COR-L311*
COR-L32
COR-L88
COR-L88*
COR-L95
COR-L95*
CPC-N
CPC-N*
DMS-114
DMS-114*
DMS-273
DMS-273*
DMS-53
DMS-53*
DMS-79
DMS-79*
EBC-1
EBC-1*
EKVX
EMC-BAC-1
EMC-BAC-2
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
77
EPLC-272H
EPLC-272H*
NCI-H3255
HARA
HARA*
HCC-15
HCC-15*
HCC-366
HCC-366*
HCC-44
HCC-44*
HCC-78
HCC-78*
HCC-827
HCC-827*
HOP-62
HOP-92
IA-LM
IA-LM*
IST-SL1
IST-SL2
KNS-62
KNS-62*
LB647-SCLC
LC-1/sq-SF
LC-1/sq-SF*
LC-2/ad
LCLC-103H
LCLC-103H*
LCLC-97TM1
LCLC-97TM1*
LK-2
LK-2*
LOU-NH91
LOU-NH91*
Lu-134A
Lu-135
Lu-139
Lu-165
Lu-65
Lu-65*
Lu-99A
LXF-289
LXF-289*
MS-1
NCI-H1048
NCI-H1048*
NCI-H1092
NCI-H1092*
NCI-H1105
NCI-H1105*
NCI-H1155
NCI-H1155*
NCI-H1299
NCI-H1299*
NCI-H1304
NCI-H1341
NCI-H1341*
NCI-H1355
NCI-H1355*
NCI-H1395
NCI-H1395*
NCI-H1417
NCI-H1435
NCI-H1435*
NCI-H1436
NCI-H1436*
NCI-H146
NCI-H146*
NCI-H1563
NCI-H1563*
NCI-H1568
NCI-H1568*
NCI-H1573
NCI-H1573*
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
78
NCI-H1581
NCI-H1581*
NCI-H1623
NCI-H1623*
NCI-H1648
NCI-H1648*
NCI-H1650
NCI-H1650*
NCI-H1651
NCI-H1651*
NCI-H1666
NCI-H1666*
NCI-H1688
NCI-H1693
NCI-H1693*
NCI-H1694
NCI-H1694*
NCI-H1703
NCI-H1703*
NCI-H1734
NCI-H1734*
NCI-H1755
NCI-H1755*
NCI-H1770
NCI-H1781
NCI-H1781*
NCI-H1792
NCI-H1792*
NCI-H1793
NCI-H1793*
NCI-H1836
NCI-H1836*
NCI-H1838
NCI-H1838*
NCI-H1869
NCI-H1869*
NCI-H187
NCI-H1876
NCI-H1876*
NCI-H1915
NCI-H1915*
NCI-H1944
NCI-H1944*
NCI-H196
NCI-H196*
NCI-H1963
NCI-H1963*
NCI-H1975
NCI-H1975*
NCI-H1993
NCI-H2009
NCI-H2009*
NCI-H2023
NCI-H2023*
NCI-H2029
NCI-H2029*
NCI-H2030
NCI-H2030*
NCI-H2066
NCI-H2066*
NCI-H2085
NCI-H2085*
NCI-H2087
NCI-H2087*
NCI-H209
NCI-H209*
NCI-H211
NCI-H211*
NCI-H2110
NCI-H2110*
NCI-H2122
NCI-H2122*
NCI-H2135
NCI-H2141
NCI-H2141*
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
79
NCI-H2170
NCI-H2170*
NCI-H2172
NCI-H2172*
NCI-H2196
NCI-H2196*
NCI-H2227
NCI-H2227*
NCI-H2228
NCI-H2228*
NCI-H226
NCI-H226*
NCI-H2291
NCI-H2291*
NCI-H23
NCI-H23*
NCI-H2342
NCI-H2342*
NCI-H2347
NCI-H2347*
NCI-H2405
NCI-H2405*
NCI-H2444
NCI-H2444*
NCI-H250
NCI-H292
NCI-H3122
NCI-H322*
NCI-H322M
NCI-H345
NCI-H358
NCI-H358*
NCI-H378
NCI-H441
NCI-H441*
NCI-H446
NCI-H446*
NCI-H510A
NCI-H520
NCI-H520*
NCI-H522
NCI-H522*
NCI-H524
NCI-H524*
NCI-H526
NCI-H526*
NCI-H596
NCI-H596*
NCI-H64
NCI-H647
NCI-H647*
NCI-H650
NCI-H650*
NCI-H661
NCI-H661*
NCI-H69
NCI-H69*
NCI-H720
NCI-H727
NCI-H727*
NCI-H748
NCI-H810
NCI-H810*
NCI-H82
NCI-H82*
NCI-H838
NCI-H838*
NCI-H841
NCI-H841*
NCI-H847
PC-14
PC-14*
PC-3 [JPC-3]
RERF-LC-KJ
RERF-LC-KJ*
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
80
RERF-LC-MS
RERF-LC-MS*
RERF-LC-Sq1
RERF-LC-Sq1*
SBC-1
SBC-3
SBC-5
SBC-5*
SHP-77
SHP-77*
SK-LU-1
SK-LU-1*
SK-MES-1
SK-MES-1*
SW-1271
SW-1271*
SW-1573
SW-1573*
SW-900
SW-900*
VMRC-LCD
VMRC-LCD*
mesothelioma
NCI-H2369
NCI-H2373
NCI-H2461
NCI-H2591
NCI-H2595
NCI-H2722
NCI-H2731
NCI-H2795
NCI-H2803
NCI-H2804
NCI-H2810
NCI-H2818
NCI-H2869
NCI-H290
NCI-H513
IST-Mes1
MPP-89
MSTO-211H
NCI-H2052
NCI-H2452
NCI-H28
other
Calu-1
COR-L24
COR-L321
COR-L47
COR-L51
DFCI-024
DMS-153
DMS-454
DV-90
HCC-1171
HCC-1195
HCC-1359
HCC-1438
HCC-1588
HCC-1833
HCC-1897
HCC-2108
HCC-2279
HCC-2814
HCC-2935
HCC-33
HCC-364
HCC-4006
HCC-827-GR5
HCC-95
HLC-1
HLF-a
Hs-229.T
Hs-618.T
LC1F
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
81
Lu-99
LUDLU-1
MOR/CPR
NCI-H1184
NCI-H1339
NCI-H1373
NCI-H1385
NCI-H1437
NCI-H1618
NCI-H1930
NCI-H2081
NCI-H2106
NCI-H2126
NCI-H2171
NCI-H2286
NCI-H292
NCI-H292*
NCI-H3255
NCI-H460
NCI-H510
NCI-H854
NCI-H889
RERF-LC-Ad1
RERF-LC-Ad2
RERF-LC-AI
SALE
SCLC-21H
Sq-1
T3-M10
TIG-3TD
VMRC-LCP
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948685.v1
Table 4.14. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Lung: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
carcinoid-endocrine tumour
NCI-H835
UMC-11
carcinoma
201T
A-427
A-549
A-549*
ABC-1
ABC-1*
BEN
BEN*
CAL-12T
CAL-12T*
CAL-U3
CAL-U3*
CAL-U6
CAL-U6*
ChaGo-K-1
ChaGo-K-1*
COLO-668
COLO-668*
COR-L105
COR-L105*
COR-L23
COR-L23*
COR-L279
COR-L279*
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
82
COR-L303
COR-L311
COR-L311*
COR-L32
COR-L88
COR-L88*
COR-L95
COR-L95*
CPC-N
CPC-N*
DMS-114
DMS-114*
DMS-273
DMS-273*
DMS-53
DMS-53*
DMS-79
DMS-79*
EBC-1
EBC-1*
EKVX
EMC-BAC-1
EMC-BAC-2
EPLC-272H
EPLC-272H*
NCI-H3255
HARA
HARA*
HCC-15
HCC-15*
HCC-366
HCC-366*
HCC-44
HCC-44*
HCC-78
HCC-78*
HCC-827
HCC-827*
HOP-62
HOP-92
IA-LM
IA-LM*
IST-SL1
IST-SL2
KNS-62
KNS-62*
LB647-SCLC
LC-1/sq-SF
LC-1/sq-SF*
LC-2/ad
LCLC-103H
LCLC-103H*
LCLC-97TM1
LCLC-97TM1*
LK-2
LK-2*
LOU-NH91
LOU-NH91*
Lu-134A
Lu-135
Lu-139
Lu-165
Lu-65
Lu-65*
Lu-99A
LXF-289
LXF-289*
MS-1
NCI-H1048
NCI-H1048*
NCI-H1092
NCI-H1092*
NCI-H1105
NCI-H1105*
NCI-H1155
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
83
NCI-H1155*
NCI-H1299
NCI-H1299*
NCI-H1304
NCI-H1341
NCI-H1341*
NCI-H1355
NCI-H1355*
NCI-H1395
NCI-H1395*
NCI-H1417
NCI-H1435
NCI-H1435*
NCI-H1436
NCI-H1436*
NCI-H146
NCI-H146*
NCI-H1563
NCI-H1563*
NCI-H1568
NCI-H1568*
NCI-H1573
NCI-H1573*
NCI-H1581
NCI-H1581*
NCI-H1623
NCI-H1623*
NCI-H1648
NCI-H1648*
NCI-H1650
NCI-H1650*
NCI-H1651
NCI-H1651*
NCI-H1666
NCI-H1666*
NCI-H1688
NCI-H1693
NCI-H1693*
NCI-H1694
NCI-H1694*
NCI-H1703
NCI-H1703*
NCI-H1734
NCI-H1734*
NCI-H1755
NCI-H1755*
NCI-H1770
NCI-H1781
NCI-H1781*
NCI-H1792
NCI-H1792*
NCI-H1793
NCI-H1793*
NCI-H1836
NCI-H1836*
NCI-H1838
NCI-H1838*
NCI-H1869
NCI-H1869*
NCI-H187
NCI-H1876
NCI-H1876*
NCI-H1915
NCI-H1915*
NCI-H1944
NCI-H1944*
NCI-H196
NCI-H196*
NCI-H1963
NCI-H1963*
NCI-H1975
NCI-H1975*
NCI-H1993
NCI-H2009
NCI-H2009*
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
84
NCI-H2023
NCI-H2023*
NCI-H2029
NCI-H2029*
NCI-H2030
NCI-H2030*
NCI-H2066
NCI-H2066*
NCI-H2085
NCI-H2085*
NCI-H2087
NCI-H2087*
NCI-H209
NCI-H209*
NCI-H211
NCI-H211*
NCI-H2110
NCI-H2110*
NCI-H2122
NCI-H2122*
NCI-H2135
NCI-H2141
NCI-H2141*
NCI-H2170
NCI-H2170*
NCI-H2172
NCI-H2172*
NCI-H2196
NCI-H2196*
NCI-H2227
NCI-H2227*
NCI-H2228
NCI-H2228*
NCI-H226
NCI-H226*
NCI-H2291
NCI-H2291*
NCI-H23
NCI-H23*
NCI-H2342
NCI-H2342*
NCI-H2347
NCI-H2347*
NCI-H2405
NCI-H2405*
NCI-H2444
NCI-H2444*
NCI-H250
NCI-H292
NCI-H3122
NCI-H322*
NCI-H322M
NCI-H345
NCI-H358
NCI-H358*
NCI-H378
NCI-H441
NCI-H441*
NCI-H446
NCI-H446*
NCI-H510A
NCI-H520
NCI-H520*
NCI-H522
NCI-H522*
NCI-H524
NCI-H524*
NCI-H526
NCI-H526*
NCI-H596
NCI-H596*
NCI-H64
NCI-H647
NCI-H647*
NCI-H650
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
85
NCI-H650*
NCI-H661
NCI-H661*
NCI-H69
NCI-H69*
NCI-H720
NCI-H727
NCI-H727*
NCI-H748
NCI-H810
NCI-H810*
NCI-H82
NCI-H82*
NCI-H838
NCI-H838*
NCI-H841
NCI-H841*
NCI-H847
PC-14
PC-14*
PC-3 [JPC-3]
RERF-LC-KJ
RERF-LC-KJ*
RERF-LC-MS
RERF-LC-MS*
RERF-LC-Sq1
RERF-LC-Sq1*
SBC-1
SBC-3
SBC-5
SBC-5*
SHP-77
SHP-77*
SK-LU-1
SK-LU-1*
SK-MES-1
SK-MES-1*
SW-1271
SW-1271*
SW-1573
SW-1573*
SW-900
SW-900*
VMRC-LCD
VMRC-LCD*
mesothelioma
NCI-H2369
NCI-H2373
NCI-H2461
NCI-H2591
NCI-H2595
NCI-H2722
NCI-H2731
NCI-H2795
NCI-H2803
NCI-H2804
NCI-H2810
NCI-H2818
NCI-H2869
NCI-H290
NCI-H513
IST-Mes1
MPP-89
MSTO-211H
NCI-H2052
NCI-H2452
NCI-H28
other
Calu-1
COR-L24
COR-L321
COR-L47
COR-L51
DFCI-024
DMS-153
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
86
DMS-454
DV-90
HCC-1171
HCC-1195
HCC-1359
HCC-1438
HCC-1588
HCC-1833
HCC-1897
HCC-2108
HCC-2279
HCC-2814
HCC-2935
HCC-33
HCC-364
HCC-4006
HCC-827-GR5
HCC-95
HLC-1
HLF-a
Hs-229.T
Hs-618.T
LC1F
Lu-99
LUDLU-1
MOR/CPR
NCI-H1184
NCI-H1339
NCI-H1373
NCI-H1385
NCI-H1437
NCI-H1618
NCI-H1930
NCI-H2081
NCI-H2106
NCI-H2126
NCI-H2171
NCI-H2286
NCI-H292
NCI-H292*
NCI-H3255
NCI-H460
NCI-H510
NCI-H854
NCI-H889
RERF-LC-Ad1
RERF-LC-Ad2
RERF-LC-AI
SALE
SCLC-21H
Sq-1
T3-M10
TIG-3TD
VMRC-LCP
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948685.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
87
Lymphoma (Lymphoma)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Lymphoma (Tabl.4.15. a. & b.), it is concluded that:
- main potential medicines are: AACF 1.C., 4.C., 5.C., 5.D., 19., 23.A., 31.B., 34., 39., 40., 45.E., 51.A., 56.A., 56.B., 57., 61.B. and 63.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.B., 1.D., 1.G., 4.A., 5.A., 5.B., 7., 12., 25., 30., 31.A., 31.C., 32., 33., 36., 37., 38., 41., 42., 43., 44., 45.B., 46., 47., 48., 49., 50., 51.B., 52., 61.A.,
62.B., and 64.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.15. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Lymphoma: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
lymphoid neoplasm
A3/Kawakami
A4/Fukuda
BC-1
BL-41
CA-46
CRO-AP2
CTB-1
Daudi
DB
DEL
DG-75
DоHH-2
EB-2
EB-3
EHEB
Farage
GA-10
GRANTA-519
H-9
HDLM-2
HD-MY-Z
Hs-445
JеKо-1
JiyoyeP-2003
JM-1
JSC-1
JVM-2
JVM-3
Karpas-1106P
Karpas-299
Karpas-422
KM-H2
L-1236
L-428
L-540
MC-116
Namalwa
NU-DUL-1
OCI-LY19
OCI-LY7
P32/ISH
Raji
Ramos-2G6-4C10
RC-K8
RL
RPMI-6666
SCC-3
SLVL
SR
ST-486
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
88
SU-DHL-1
SU-DHL-10
SU-DHL-16
SU-DHL-4
SU-DHL-5
SU-DHL-6
SUP-HD1
SUP-M2
TK
TUR
VAL
WIL2-NS
WSU-DLCL2
WSU-NHL
YT
other
SU-DHL-8
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948676.v1
Table 4.15. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Lymphoma: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
lymphoid neoplasm
A3/Kawakami
A4/Fukuda
BC-1
BL-41
CA-46
CRO-AP2
CTB-1
Daudi
DB
DEL
DG-75
DоHH-2
EB-2
EB-3
EHEB
Farage
GA-10
GRANTA-519
H-9
HDLM-2
HD-MY-Z
Hs-445
JеKо-1
JiyoyeP-2003
JM-1
JSC-1
JVM-2
JVM-3
Karpas-1106P
Karpas-299
Karpas-422
KM-H2
L-1236
L-428
L-540
MC-116
Namalwa
NU-DUL-1
OCI-LY19
OCI-LY7
P32/ISH
Raji
Ramos-2G6-4C10
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
89
RC-K8
RL
RPMI-6666
SCC-3
SLVL
SR
ST-486
SU-DHL-1
SU-DHL-10
SU-DHL-16
SU-DHL-4
SU-DHL-5
SU-DHL-6
SUP-HD1
SUP-M2
TK
TUR
VAL
WIL2-NS
WSU-DLCL2
WSU-NHL
YT
other
SU-DHL-8
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948676.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
90
Myeloma (Myeloma)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Myeloma (Tabl.4.16. a. & b.), it is concluded that:
- main potential medicines are: AACF 1.B., 1.C., 1.D., 4.A., 4.C., 5.A., 5.B., 5.C., 5.D., 7., 12., 19., 23.A., 30., 31.A., 31.B., 31.C., 32., 33., 34., 36., 37., 38., 39., 40., 42., 43., 44., 45.B., 45.E., 46., 48., 49., 50., 51.A., 51.B.,
52., 55., 56.A., 56.B., 57., 60., 61.A., 61.B., 62.B., 63. and 64.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.G., 4.B., 25., 58. and 59.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.16. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Myeloma: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
lymphoid neoplasm
AMO-1
ARH-77
EJM
IM-9
JJN-3
Karpas-620
KMS-11
KMS-12-BM
L-363
LP-1
MC/CAR
MM.1S
MOLP-8
NCI-H929
OPM-2
RPMI-8226
SK-MM-2
U-266
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948673.v1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
91
Table 4.16. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Myeloma: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
lymphoid neoplasm
AMO-1
ARH-77
EJM
IM-9
JJN-3
Karpas-620
KMS-11
KMS-12-BM
L-363
LP-1
MC/CAR
MM.1S
MOLP-8
NCI-H929
OPM-2
RPMI-8226
SK-MM-2
U-266
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948673.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
92
Neuroblastoma (Neuroblastoma)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Neuroblastoma (Tabl.4.17. a. & b.), it is concluded that:
- main potential medicines are: AACF 4.C., 5.C., 5.D., 23.A., 31.B., 34., 39., 40., 45.E., 56.B., 57. and 63.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.C., 19., 30., 31.C., 37., 44., 46., 48., 51.A., 56.A., 61.A., 61.B. and 62.B.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.17. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Neuroblastoma: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
neuroblastoma
BE(2)-M17
CHP-126
CHP-134
CHP-212
GI-ME-N
GOTO
IMR-5
Kelly
KP-N-YN
LAN-6
MHH-NB-11
NB(TU)1-10
NB-1
NB-10
NB-12
NB-13
NB-14
NB-17
NB-5
NB-6
NB-69
NB-7
NH-12
SiMa
SK-N-AS
SK-N-DZ
SK-N-FI
SK-N-SH
TGW
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948667.v1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
93
Table 4.17. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Neuroblastoma: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
neuroblastoma
BE(2)-M17
CHP-126
CHP-134
CHP-212
GI-ME-N
GOTO
IMR-5
Kelly
KP-N-YN
LAN-6
MHH-NB-11
NB(TU)1-10
NB-1
NB-10
NB-12
NB-13
NB-14
NB-17
NB-5
NB-6
NB-69
NB-7
NH-12
SiMa
SK-N-AS
SK-N-DZ
SK-N-FI
SK-N-SH
TGW
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948667.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
94
Nervous system (Systema nervosum)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Nervous system (Tabl.4.18. a. & b.), it is concluded that:
- main potential medicines are: AACF 4.C., 5.C., 19., 23.A., 34., 39., 40., 56.B. and 63.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.C., 5.D., 12., 31.B., 45.E., 51.A., 56.A., 61.B. and 64.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.18. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Nervous system: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
glioma
42-MG-BA
8-MG-BA
A-172
AM-38
Becker
CAS-1
CCF-STTG1
D-247MG
D-263MG
D-336MG
D-392MG
D-423MG
D-502MG
D-542MG
D-566MG
DBTRG-05MG
DK-MG
GaMG
GB-1
GI-1
GMS-10
H-4
Hs-683
KALS-1
KINGS-1
KNS-42
KNS-81-FD
KS-1
LN-18
LN-229
LN-405
LNZTA3WT4
M-059J
MOG-G-CCM
MOG-G-UVW
NMC-G1
no-10
no-11
SF-126
SF-268
SF-295
SF-539
SK-MG-1
SNB-75
SW-1088
SW-1783
T98G
U-118MG
U-251
U-87MG
YH-13
YKG-1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
95
primitive neuroectodermal tumour-medulloblastoma
D-283MED
Daoy
ONS-76
PFSK-1
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948670.v1
Table 4.18. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Nervous system: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
glioma
42-MG-BA
8-MG-BA
A-172
AM-38
Becker
CAS-1
CCF-STTG1
D-247MG
D-263MG
D-336MG
D-392MG
D-423MG
D-502MG
D-542MG
D-566MG
DBTRG-05MG
DK-MG
GaMG
GB-1
GI-1
GMS-10
H-4
Hs683
KALS-1
KINGS-1
KNS-42
KNS-81-FD
KS-1
LN-18
LN-229
LN-405
LNZTA3WT4
M-059J
MOG-G-CCM
MOG-G-UVW
NMC-G1
no-10
no-11
SF-126
SF-268
SF-295
SF-539
SK-MG-1
SNB-75
SW-1088
SW-1783
T-98G
U-118MG
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
96
U-251
U-87MG
YH-13
YKG-1
primitive neuroectodermal tumour-medulloblastoma
D-283MED
Daoy
ONS-76
PFSK-1
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23948670.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies.
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
97
Oesophagus (Oesophagus)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Oesophagus (Tabl.4.19. a. & b.) it is concluded that:
- main potential medicines are: AACF 1.B., 1.C., 1.D., 4.A., 4.C., 5.A., 5.B., 5.C., 5.D., 7., 12., 19., 23.A., 30., 31.A., 31.B., 32., 33., 34., 36., 37., 38., 39., 40., 43., 44., 45.B., 45.E., 46., 48., 49., 51.A., 51.B., 52., 56.A.,
56.B., 57., 60., 61.A., 61.B., 62.B., 63. and 64.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.G., 4.B., 5.B., 25., 31.C., 42., 50., 55. and 59.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.19. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Oesophagus: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
carcinoma
OE-19
TT
other
COLO-680N
EC-GI-10
JH-EsoAd1
KYSE-140
KYSE-150
KYSE-180
KYSE-270
KYSE-30
KYSE-410
KYSE-450
KYSE-510
KYSE-520
KYSE-70
OE-33
TE--1
TE-10
TE-11
TE-14
TE-15
TE-4
TE-5
TE-6
TE-8
TE-9
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23947329.v1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
98
Table 4.19. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Oesophagus: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
carcinoma
OE-19
TT
other
COLO-680N
EC-GI-10
JH-EsoAd1
KYSE-140
KYSE-150
KYSE-180
KYSE-270
KYSE-30
KYSE-410
KYSE-450
KYSE-510
KYSE-520
KYSE-70
OE-33
TE--1
TE-10
TE-11
TE-14
TE-15
TE-4
TE-5
TE-6
TE-8
TE-9
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23947329.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
99
Ovary (Ovarium)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Ovary (Tabl.4.20. a & b), it is concluded that:
- main potential medicines are: AACF 4.C., 5.C., 5.D., 23.A., 31.B., 34., 40., 51.A., 56.B. and 63.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.C., 19., 30., 31.A., 31.C., 32., 33., 39., 45.E., 46., 48., 51.A., 55., 56.A., 57., 61.A. and 61.B.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.20. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Ovary: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
carcinoma
A-2780
Kuramochi
OVISE
OVKATE
OVTOKO
other
59M
Caov-3
Caov-4
COLO-704
COV-318
COV-362
COV-434
COV-504
COV-644
EFO-21
EFO-27
ES-2
FU-OV-1
HEY-A8
Hс-571.T
IGROV-1
JHOC-5
JHOM-1
JHOM-2B
JHOS-2
JHOS-4
MCAS
NIH-OVCAR-3
OAW-28
OAW-42
OC-314
OC-315
OC-316
OELE
ONCO-DG1
OV-56
OV-7
OV-90
OVCAR-4
OVCAR-8
OVK-18
OVMANA
OVSAHO
RMG-I
RMUG-S
SK-OV-3
SNU-119
SNU-8
SNU-840
TOV-112D
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
100
TOV-21G
TYK-nu
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23947314.v1
Table 4.20. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Ovary: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
carcinoma
A-2780
Kuramochi
OVISE
OVKATE
OVTOKO
other
59M
Caov-3
Caov-4
COLO-704
COV-318
COV-362
COV-434
COV-504
COV-644
EFO-21
EFO-27
ES-2
FU-OV-1
HEY-A8
Hс-571.T
IGROV-1
JHOC-5
JHOM-1
JHOM-2B
JHOS-2
JHOS-4
MCAS
NIH-OVCAR-3
OAW-28
OAW-42
OC-314
OC-315
OC-316
OELE
ONCO-DG1
OV-56
OV-7
OV-90
OVCAR-4
OVCAR-8
OVK-18
OVMANA
OVSAHO
RMG-I
RMUG-S
SK-OV-3
SNU-119
SNU-8
SNU-840
TOV-112D
TOV-21G
TYK-nu
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23947314.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
101
Pancreas (Pancreas)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Pancreas (Tabl.4.21 a & b), it is concluded that:
- main potential medicines are: AACF 4.C., 5.C., 31.B., 40., 51.A., 56.B. and 64.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.C., 5.D., 19., 23.А., 34., 39., 44., 45.E., 56.A. and 61.B.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.21. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Pancreas: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
carcinoma
AsPC-1
AsPC-1*
BxPC-3
BxPC-3*
Capan-1
Capan-1*
Capan-2
Capan-2*
CFPAC-1
CFPAC-1*
DANG
DANG*
HPAC
HPAC*
HPAF-II
HPAF-II*
Hs-766T
Hs-766T*
HUP-T3
HUP-T3*
HUP-T4
HUP-T4*
KP-1N
KP-3
KP-3*
KP-4
KP-4*
MIA-PaCa-2
MIA-PaCa-2*
MZ-1-PC
PANC-0203
PANC-0203*
PANC-0327
PANC-0327*
PANC-0403
PANC-0403*
PANC-0813
PANC-0813*
PANC-1005
PANC-1005*
PaTu-8902
PaTu -8902*
PaTu -8988T
PaTu -8988T*
PL-18
PL-4
PSN-1
PSN-1*
QGP-1
QGP-1*
SU-8686
SU-8686*
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
102
SUIT-2
SUIT-2*
SW-1990
SW-1990*
YAPC
YAPC*
other
KCI-MOH1
KLM-1
KP-2
KP-2*
L-33
PANC-0213
PANC-0504
PANC-1
PaTu-8988S
PK-1
PK-45H
PK-59
PL-45
SNU-213
SNU-324
SNU-410
T3M-4
TCC-Pan2
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23947296.v1
Table 4.21. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Pancreas: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
45
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
carcinoma
AsPC-1
AsPC-1*
BxPC-3
BxPC-3*
Capan-1
Capan-1*
Capan-2
Capan-2*
CFPAC-1
CFPAC-1*
DANG
DANG*
HPAC
HPAC*
HPAF-II
HPAF-II*
Hs-766T
Hs-766T*
HUP-T3
HUP-T3*
HUP-T4
HUP-T4*
KP-1N
KP-3
KP-3*
KP-4
KP-4*
MIA-PaCa-2
MIA-PaCa-2*
MZ-1-PC
PANC-0203
PANC-0203*
PANC-0327
PANC-0327*
PANC-0403
PANC-0403*
PANC-0813
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
103
PANC-0813*
PANC-1005
PANC-1005*
PaTu-8902
PaTu -8902*
PaTu -8988T
PaTu -8988T*
PL-18
PL-4
PSN-1
PSN-1*
QGP-1
QGP-1*
SU-8686
SU-8686*
SUIT-2
SUIT-2*
SW-1990
SW-1990*
YAPC
YAPC*
other
KCI-MOH1
KLM-1
KP-2
KP-2*
L-33
PANC-0213
PANC-0504
PANC-1
PaTu-8988S
PK-1
PK-45H
PK-59
PL-45
SNU-213
SNU-324
SNU-410
T3M-4
TCC-Pan2
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23947296.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
104
Pleura (Pleurae)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Pleura (Tabl.4.22. a. & b.), it is concluded that:
- main potential medicines are: AACF 1.C., 1.B., 1.D., 1.G., 4.A., 4.B., 4.C., 5.A., 5.B., 5.C., 5.D., 7., 12., 19., 23.A., 30., 31.A., 31.B., 31.C., 32., 33., 34., 36., 37., 38., 39., 40., 42., 43., 44., 45.B., 45.E., 46., 48., 49., 50.,
51.A., 51.B., 52., 55., 56.A., 56.B., 57., 58., 59., 60., 61.A., 61.B., 62.B., 63. and 64.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.A., 11., 14., 25., 41. and 47.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.22. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Pleura: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
ACC-MESO-1
DM-3
IST-Mes-1
IST-Mes-2
JL-1
MPP-89
MSTO-211H
NCI-H2052
NCI-H2452
NCI-H28
RS-5
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23947251.v1
Table 4.22. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Pleura: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
ACC-MESO-1
DM-3
IST-Mes-1
IST-Mes-2
JL-1
MPP-89
MSTO-211H
NCI-H2052
NCI-H2452
NCI-H28
RS-5
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23947251.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
105
Prostate (Prostata)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Prostate (Tabl.4.23. a. & b.), it is concluded that:
- main potential medicines are: AACF 1.C., 4.C., 5.A., 5.C., 5.D., 12., 19., 23.A., 31.A., 31.B., 34., 39., 40., 45.E., 48., 51.A., 56.A., 56.B., 57., 61.A. and 63.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.B., 1.D., 1.G., 4.A., 4.B., 5.B., 7., 25., 30., 31.C., 32., 33., 36., 37., 38., 42., 43., 44., 45B., 46., 49., 51.B., 52., 55., 59., 60., 61.B., 62.B. and 64.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.23. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Prostate: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
carcinoma
22Rv-1
other
DU-145
LNCaP clone FGC
MDA-PCa-2b
NCI-H660
PC-3
PrEC-LH
VCaP
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23947215.v1
Table 4.23. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Prostate: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
carcinoma
22Rv-1
other
DU-145
LNCaP clone FGC
MDA-PCa-2b
NCI-H660
PC-3
PrEC-LH
VCaP
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23947215.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
106
Salivary gland (Glandulae salivariae oris)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Salivary grand (Tabl.4.24. a. & b.), it is concluded that:
- main potential medicines are: AACF 1.A., 1.B., 1.C., 1.D., 1.G., 4.A., 4.B., 4.C., 5.A., 5.B., 5.C., 5.D., 7., 9., 11., 12., 14., 19., 23.A., 25., 30., 31.A., 31.B., 31.C., 32., 33., 34., 36., 37., 38., 39., 40., 41., 42., 43., 44., 45.B.,
45.E., 45.H., 46., 47., 48., 49., 50., 51.A., 51.B., 56.A., 56.B., 57., 58., 59., 60., 61.A., 61.B., 63. and 64.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.E., 1.F., 1.H., 2.A., 3., 6., 8., 10., 15., 17., 18., 20.A., 20.B., 21., 22., 26., 27., 28., 35., 45.C., 53.B., 54., and 62.A.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.24. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Salivary gland: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
carcinoma
A-253
other
YD-15
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23947068.v1
Table 4.24. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Salivary gland: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
carcinoma
A-253
other
YD-15
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23947068.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
107
Skin (Cutis)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Skin (Tabl.4.25. a. & b.), it is concluded that:
- main potential medicines are: AACF 4.C., 5.C., 5.D., 12., 19., 23.A., 31.B., 34., 39., 40., 45.E., 51.A., 56.A., 56.B., 57. and 63.;
- duplication of treatment and/or substitution on medical grounds: AACF 1.B., 1.C., 5.A., 30., 31.A., 31.C., 33., 37., 44., 45.B., 46., 48., 49., 51.B., 52., 59., 60., 61.A., 61.B. and 64.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.25. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Skin: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
adnexal tumour
DJM-1
carcinoma
A-388
A-431
malignant melanoma
451-Lu
A-101D
A-101D*
A-2058
A-2058*
A-375
A-375*
C-32
C-32*
CHL-1
CHL-1*
COLO-679
COLO-679*
COLO-783
COLO-783*
COLO-792
COLO-792*
COLO-800
COLO-800*
COLO-829
COLO-829*
CP50-MEL-B
CP66-MEL
G-361
G-361*
GAK
G-MEL
HMV-II
Hs-940T
Hs-940T*
HT-144
HT-144*
IGR-1
IGR-1*
IGR-37
IGR-37*
IPC-298
IPC-298*
IST-MEL-1
K-2
LB2518-MEL
LB373-MEL-D
LOX-IMVI
LOX-IMVI*
M-14
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
108
MEL-HO
MEL-HO*
MEL-JUSO
MEL-JUSO*
MeWo
MeWo*
MMAc-SF
MZ2-MEL
MZ7-MEL
RPMI-7951
RPMI-7951*
RVH-421
RVH-421*
SH-4
SH-4*
SK-MEL-1
SK-MEL-1*
SK-MEL-2
SK-MEL-2*
SK-MEL-24
SK-MEL-24*
SK-MEL-28
SK-MEL-28*
SK-MEL-3
SK-MEL-3*
SK-MEL-30
SK-MEL-30*
SK-MEL-31
SK-MEL-31*
SK-MEL-5
SK-MEL-5*
UACC-257
UACC-257*
UACC-62
UACC-62*
WM-115
WM-115*
WM-1552C
WM-278
WM-35
WM-793B
other
BJ-hTERT
CJM
COLO-741
COLO-818
COLO-849
GR-M
HMCB
Hs-294T
Hs-600T
Hs-688AT
Hs-695T
Hs-834T
Hs-839T
Hs-852T
Hs-895T
Hs-934T
Hs-936T
Hs-939T
Hs-944T
IGR-39
K-029-AX
Malme-3M
MDA-MB-435S
WM-1799
WM-2664
WM-793
WM-88
WM-983B
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23947014.v1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
109
Table 4.25. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Skin: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
adnexal tumour
DJM-1
carcinoma
A-388
A-431
malignant melanoma
451-Lu
A-101D
A-101D*
A-2058
A-2058*
A-375
A-375*
C-32
C-32*
CHL-1
CHL-1*
COLO-679
COLO-679*
COLO-783
COLO-783*
COLO-792
COLO-792*
COLO-800
COLO-800*
COLO-829
COLO-829*
CP50-MEL-B
CP66-MEL
G-361
G-361*
GAK
G-MEL
HMV-II
Hs-940T
Hs-940T*
HT-144
HT-144*
IGR-1
IGR-1*
IGR-37
IGR-37*
IPC-298
IPC-298*
IST-MEL-1
K-2
LB2518-MEL
LB373-MEL-D
LOX-IMVI
LOX-IMVI*
M-14
MEL-HO
MEL-HO*
MEL-JUSO
MEL-JUSO*
MeWo
MeWo*
MMAc-SF
MZ2-MEL
MZ7-MEL
RPMI-7951
RPMI-7951*
RVH-421
RVH-421*
SH-4
SH-4*
SK-MEL-1
SK-MEL-1*
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
110
SK-MEL-2
SK-MEL-2*
SK-MEL-24
SK-MEL-24*
SK-MEL-28
SK-MEL-28*
SK-MEL-3
SK-MEL-3*
SK-MEL-30
SK-MEL-30*
SK-MEL-31
SK-MEL-31*
SK-MEL-5
SK-MEL-5*
UACC-257
UACC-257*
UACC-62
UACC-62*
WM-115
WM-115*
WM-1552C
WM-278
WM-35
WM-793B
other
BJ-hTERT
CJM
COLO-741
COLO-818
COLO-849
GR-M
HMCB
Hs-294T
Hs-600T
Hs-688AT
Hs-695T
Hs-834T
Hs-839T
Hs-852T
Hs-895T
Hs-934T
Hs-936T
Hs-939T
Hs-944T
IGR-39
K-029-AX
Malme-3M
MDA-MB-435S
WM-1799
WM-2664
WM-793
WM-88
WM-983B
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23947014.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
111
Small intestine (Intestinum tenue)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Small intestine (Tabl.4.26. a. & b.) it is concluded that:
- main potential medicines are: AACF 1.C., 4.C., 5.A., 5.C., 5.D., 19., 23.A., 31.B., 31.C., 32., 34., 39., 40., 45.E., 51.A., 51.B., 52., 56.A., 56.B., 57., 61.A., 61.B., 62.B., 63. and 64.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.A., 1.D., 1.G., 4.A., 4.B., 5.B., 7., 9., 11., 12., 14., 25., 30., 31.A., 33., 36., 37., 38., 41., 42., 43., 44., 45.B., 45.H., 46., 47., 48., 49., 50., 55., 58.,
59. and 60.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.26. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Small intestine: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
other
HuTu-80
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23946819.v1
Table 4.26. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Small intestine: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
other
HuTu-80
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23946819.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
112
Soft tissue (Mollis textus)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Soft tissue (Tabl.4.27. a & b.), it is concluded that:
- main potential medicines are: AACF 5.C. and 40.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.B., 1.C., 1.D., 4.C., 5.D., 12., 19., 23.A., 30., 31.A., 31.B., 31.C., 32., 33., 34., 36., 37., 38., 39., 42., 43., 44., 45.B., 45.E., 46., 48., 49., 51.A.,
51.B., 56.A., 56.B., 57., 60., 61.A., 61.B., 63. and 64.
,
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.27. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Soft tissue: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
Ewings sarcoma-peripheral primitive neuroectodermal tumour
A-673
fibrosarcoma
HT-1080
HT-1080*
SW-684
leiomyoblastoma
G-402
G-402*
leiomyosarcoma
SK-UT-1
SK-UT-1*
liposarcoma
SW-872
malignant fibrous histiocytoma-pleomorphic sarcoma
GCT
GCT*
MFH-ino
rhabdomyosarcoma
A-204
A-204*
KYM-1
KYM-1*
RD
RD*
RH-1
RH-18
RH-18*
RH-41
RH-41*
SJRh-30
SJRh-30*
TE-441.T
TE-441.T*
sarcoma
SKLMS1
SKLMS1*
VA-ES-BJ
synovial sarcoma
SW-982
other
G-401
Hs-633T
Hs-729
MES-SA
Rh-30
RKN
S-117
STS-0421
TE-125.T
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
113
TE-159.T
TE-617.T
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23946789.v1
Table 4.27. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Soft tissue: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
Ewings sarcoma-peripheral primitive neuroectodermal tumour
A-673
fibrosarcoma
HT-1080
HT-1080*
SW-684
leiomyoblastoma
G-402
G-402*
leiomyosarcoma
SK-UT-1
SK-UT-1*
liposarcoma
SW-872
malignant fibrous histiocytoma-pleomorphic sarcoma
GCT
GCT*
MFH-ino
rhabdomyosarcoma
A-204
A-204*
KYM-1
KYM-1*
RD
RD*
RH-1
RH-18
RH-18*
RH-41
RH-41*
SJRh-30
SJRh-30*
TE-441.T
TE-441.T*
sarcoma
SKLMS1
SKLMS1*
VA-ES-BJ
synovial sarcoma
SW-982
other
G-401
Hs-633T
Hs-729
MES-SA
Rh-30
RKN
S-117
STS-0421
TE-125.T
TE-159.T
TE-617.T
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23946789.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
114
Stomach (Stomachus)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Stomach (Tabl.4.28. a. & b.), it is concluded that:
- main potential medicines are: AACF 1.B., 1.C., 4.C., 5.A., 5.C., 5.D., 12., 19., 23.A., 30., 31.A., 31.B., 31.C., 33., 34., 36., 37., 38., 39., 40., 43., 44., 45.B., 45.E., 46., 48., 49., 51.A., 51.B., 52., 56.A., 56.B., 57., 61.A.,
61.B., 62.B., 63. and 64.;
- duplication of treatment and/or substitution on medical grounds: AACF 1.A., 1.D., 1.G., 4.A., 4.B., 5.B., 7., 25., 32., 50., 55., 58., 59. and 60.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.28. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Stomach: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
carcinoma
AGS
ECC-10
ECC-12
FU-97
GCIY
KATO-III
MKN-1
MKN-45
MKN-7
TGBC-11-TKB
other
23132/87
AZ-521
GSS
GSU
HGC-27
Hs-746.T
HUG-1N
IM-95
KE-39
LMSU
MKN-74
NCC-StC-K140
NCI-N87
NUGC-2
NUGC-3
NUGC-4
OCUM-1
RERF-GC-1B
SH-10-TC
SNU-1
SNU-16
SNU-216
SNU-5
SNU-520
SNU-601
SNU-620
SNU-668
SNU-719
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23946132.v1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
115
Table 4.28. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Stomach: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
carcinoma
AGS
ECC-10
ECC-12
FU-97
GCIY
KATO-III
MKN-1
MKN-45
MKN-7
TGBC-11-TKB
other
23132/87
AZ-521
GSS
GSU
HGC-27
Hs-746.T
HUG-1N
IM-95
KE-39
LMSU
MKN-74
NCC-StC-K140
NCI-N87
NUGC-2
NUGC-3
NUGC-4
OCUM-1
RERF-GC-1B
SH-10-TC
SNU-1
SNU-16
SNU-216
SNU-5
SNU-520
SNU-601
SNU-620
SNU-668
SNU-719
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23946132.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
116
Thyroid (Glandula thyreoidea)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Thyroid (Tabl.4.29. a. & b.), it is concluded that:
- main potential medicines are: AACF 5.C., 56.B. and 63.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.B., 1.C., 4.C., 5.D., 23.A., 31.B., 34., 39., 40., 45.E., 48., 51.A., 57. and 61.B.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.29. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Thyroid: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
carcinoma
8305-C
8305-C*
8505-C
8505-C*
ASH-3
B-CPAP
B-CPAP*
BHT-101
BHT-101*
CAL-62
CAL-62*
CGTH-W1
CGTH-W1*
FTC-133
FTC-133*
HTC-C3
IHH-4
K5
ML-1
ML-1*
RO82-W-1
TT
TT*
TT2609-C02
TT2609-C02*
other
FTC-238
SW-579
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23945304.v1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
117
Table 4.29. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Thyroid: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
carcinoma
8305-C
8305-C*
8505-C
8505-C*
ASH-3
B-CPAP
B-CPAP*
BHT-101
BHT-101*
CAL-62
CAL-62*
CGTH-W1
CGTH-W1*
FTC-133
FTC-133*
HTC-C3
IHH-4
K5
ML-1
ML-1*
RO82-W-1
TT
TT*
TT2609-C02
TT2609-C02*
other
FTC-238
SW-579
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23945304.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
118
Upper aerodigestive tract (Tractus superior aerodigestive)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Upper aerodigestive tract (Tabl.4.30. a. & b.), it is concluded that:
- main potential medicines: AACF 1.B., 1.C., 1.D., 4.C., 5.A., 5.B., 5.C., 5.D., 7., 12., 19., 23.A., 30., 31.A., 31.B., 31.C., 32., 33., 34., 36., 37., 38., 39., 40., 43., 44., 45.B., 45.E., 46., 48., 49., 51.A., 51.B., 52., 56.A., 56.B.,
57., 60., 61.A., 61.B., 62.B., 63. and 64.;
- duplication of treatment and / or substitution on medical grounds: AACF 4.A., 42., 50., 55., 58. and 59.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.30. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Upper aerodigestive tract: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
carcinoma
BHY
BICR-22
BICR-31
FaDu
other
BICR-16
BICR-18
BICR-56
BICR-6
CAL-27
CAL-33
Detroit-562
Hs-840.T
HsC-2
HSC-3
HSC-4
PE/CA-PJ15
PE/CA-PJ34 clone C12
PE/CA-PJ41 cloned 2
PECA-PJ49
SCC-15
SCC-25
SCC-4
SCC-9
SNU-1041
SNU-1066
SNU-1076
SNU-1214
SNU-46
SNU-899
YD-10B
YD-38
YD-8
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23944968.v1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
119
Table 4.30. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Upper aerodigestive tract: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
64
65
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
carcinoma
BHY
BICR-22
BICR-31
FaDu
other
BICR-16
BICR-18
BICR-56
BICR-6
CAL-27
CAL-33
Detroit-562
Hs-840.T
HsC-2
HSC-3
HSC-4
PE/CA-PJ15
PE/CA-PJ34 clone C12
PE/CA-PJ41cloned2
PECA-PJ49
SCC-15
SCC-25
SCC-4
SCC-9
SNU-1041
SNU-1066
SNU-1076
SNU-1214
SNU-46
SNU-899
YD-10B
YD-38
YD-8
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23944968.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
120
Urinary tract (Tractus urinarii)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Urinary tract (Tabl.4.31. a. & b.), it is concluded that:
- main potential medicines are: AACF 1.B., 1.C., 1.D., 1.G., 4.A., 4.B., 4.C., 5.A., 5.B., 5.C., 5.D., 7., 12., 19., 23.A., 25., 30., 31.A., 31.B., 31.C., 32., 33., 34., 36., 37., 38., 39., 40., 43., 44., 45.B., 45.E., 46., 48., 49., 51.A.,
51.B., 52., 56.A., 56.B., 57., 60., 61.A., 61.B., 62.B., 63. and 64.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.А., 9., 42., 47., 50., 55., 58. and 59.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.31. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Urinary tract: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
carcinoma
5637
J-82
RT-4
SW-1710
SW-780
TCCSUP
other
253-J
253-JBV
639-V
647-V
BC-3C
BFTC-905
CAL-29
Hs-172.T
HT-1197
HT-1376
JM(SU)-1
KMBC-2
KU-1919
RT-112
RT-11284
SCaBER
T-24
UB-LC-1
UM-UC-1
UM-UC-3
VM-CUB-1
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23944623.v1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
121
Table 4.31. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Urinary tract: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
carcinoma
5637
J-82
RT-4
SW-1710
SW-780
TCCSUP
other
253-J
253-JBV
639-V
647-V
BC-3C
BFTC-905
CAL-29
Hs-172.T
HT-1197
HT-1376
JM(SU)-1
KMBC-2
KU-1919
RT-112
RT-11284
SCaBER
T-24
UB-LC-1
UM-UC-1
UM-UC-3
VM-CUB-1
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23944623.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
122
Urogenital system (Systema urogenitale)
From the data on the interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane (Tabl. 1) of
transcriptome cell lines inherent in tumors in the Urogenital system (Tabl.4.32. a. & b.), it is concluded that:
- main potential medicines are: AACF 4.C., 5.C., 23.A., 33., 40., 51.A., 51.B., 56.B. and 63.;
- duplication of treatment and/or substitution on medical grounds: AACF 1.C., 5.D., 19., 31.B., 34., 39., 44., 45.E., 46., 48., 51.A., 56.A. and 57.
Must read: APPLYING THE RESULTS and CLINICAL CONTROL
※
Table 4.32. a Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Urogenital system: Part 1
active anti-cancer molecular forms
cell line
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
A
B
C
D
E
F
G
H
A
B
C
A
B
C
A
B
C
D
A
B
A
B
A
B
C
D
carcinoma
5637
22Rv1
639-V
647-V
A-2780
AN3-CA
BFTC-905
C-33 A
C-4-I
CAL-29
CAL-39
Caov-4
Ca-Ski
COLO-684
DoTc2-4510
DOV-13
DSH1
DU-145
EFO-21
EFO-27
EN
ES-2
ESS-1
FU-OV-1
HEC-1
HeLa
Hey
HT-1197
HT-1376
HT-3
IGROV-1
J82
JHOS-2
JHOS-3
JHOS-4
KLE
KU-19-19
Kuramochi
LB831-BLC
LNCaP clone FGC
ME-180
MFE-280
MFE-296
MFE-319
MS-751
OAW-28
OAW-42
OC-314
OV-17R
OV-56
OV-7
OV-90
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
123
OVCA-420
OVCAR-3
OVCAR-4
OVCAR-5
OVCAR-8
OVISE
OVK-18
OVKATE
OVMIU
OVTOKO
PC-3
PEO-1
RL95-2
RMG-I
RT-112
RT4
SiHa
SISO
SKG-IIIa
SK-OV-3
SNG-M
SW-1710
SW-626
SW-756
SW-780
SW-954
SW-962
T-24
TCCSUP
TC-YIK
TOV-112D
TOV-21G
TYK-nu
UM-UC-3
UWB1.289
VCaP
VM-CUB-1
choriocarcinoma
JAR
JEG-3
germ cell tumour
NEC8
NTERA-2 cl.D1
PA-1
hyperplasia
BPH-1
leiomyosarcoma
SKN
sarcoma
MES-SA
sex cord-stromal tumour
KGN
other
PWR-1E
RKN
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23943087.v1
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
124
Table 4.32. b Interpretable prognosis of sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules (obtained after passage through the cell membrane), based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors in the Urogenital system: Part 2
active anti-cancer molecular forms
cell line
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
A
B
C
A
B
C
D
E
F
G
H
A
B
A
B
A
B
A
B
A
B
carcinoma
5637
22Rv1
639-V
647-V
A-2780
AN3-CA
BFTC-905
C-33 A
C-4-I
CAL-29
CAL-39
Caov-4
Ca-Ski
COLO-684
DoTc2-4510
DOV-13
DSH1
DU-145
EFO-21
EFO-27
EN
ES-2
ESS-1
FU-OV-1
HEC-1
HeLa
Hey
HT-1197
HT-1376
HT-3
IGROV-1
J82
JHOS-2
JHOS-3
JHOS-4
KLE
KU-19-19
Kuramochi
LB831-BLC
LNCaP clone FGC
ME-180
MFE-280
MFE-296
MFE-319
MS-751
OAW-28
OAW-42
OC-314
OV-17R
OV-56
OV-7
OV-90
OVCA-420
OVCAR-3
OVCAR-4
OVCAR-5
OVCAR-8
OVISE
OVK-18
OVKATE
OVMIU
OVTOKO
PC-3
PEO-1
RL95-2
RMG-I
RT-112
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
125
RT4
SiHa
SISO
SKG-IIIa
SK-OV-3
SNG-M
SW-1710
SW-626
SW-756
SW-780
SW-954
SW-962
T-24
TCCSUP
TC-YIK
TOV-112D
TOV-21G
TYK-nu
UM-UC-3
UWB1.289
VCaP
VM-CUB-1
choriocarcinoma
JAR
JEG-3
germ cell tumour
NEC8
NTERA-2 cl.D1
PA-1
hyperplasia
BPH-1
leiomyosarcoma
SKN
sarcoma
MES-SA
sex cord-stromal tumour
KGN
other
PWR-1E
RKN
color scale of activity - in the direction of decrease:
DOI: 10.6084/m9.figshare.23943087.v1
Other pharmaceutical forms would be highly active and potential agents for personalized therapies. Must read: APPLYING THE RESULTS and CLINICAL CONTROL
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
RESULTS ANALYSIS
In Fig.1 present (§III.3.4.2, Tsanov & Tsanov, 2023) the descriptive dependences of the
interpretable predictions of sensitivity to active anti-cancer molecular forms of transcriptional cell lines
inherent in tumors of different nature.
DOI: 10.6084/m9.figshare.24013743.v1
Figure 1 Schematic representation of the descriptive dependences of the interpretable prognosis of
sensitivity to active pharmaceutical forms for oral use and their corresponding active anti-cancer
molecules (obtained after passage through the cell membrane), based on amides/carboxylic acids -
hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
They highlight some molecular forms that are extremely active. These are: for basic
pharmaceutical forms /sorted by total activity/ – 5.C., 56.B., 4.C., 40., 63., 23.A., 5.D., 19., 31.B., 51.A.,
56.A. and 34.; for substitute forms – 48., 44., 1.D., 55., 1.C., 46., 33., 59., 45.E., 4.A. and 42.
The final breakdown by active group and pharmaceutical form is presented in the front section.
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
127
APPLYING THE RESULTS
The results of the analysis show that the studied molecular forms do NOT contradict conservative
oncology. Their activity is significant and many times exceeds a number of approved products for
treatment (§IV.3.2., p.718; Tsanov & Tsanov, 2023) (Tsanov & Tsanov, 2022).
This anti-cancer agents could best be administered orally (§IV.1., p.57; Tsanov & Tsanov, 2023)..
Their toxicity is many times less than that of most references accepted in clinical chemotherapy
(§IV.3.1., p.85; Tsanov & Tsanov, 2023) (Tsanov & Tsanov, 2020).
After analyzing the conclusions on the previous goals of the research (§IV.1÷3., p.718; Tsanov &
Tsanov, 2023) (Tsanov & Tsanov, 2021), taking into account the presented clinical control, the data for
the interpretable prognosis for susceptibility to active anti-cancer molecular forms of transcriptome cell
lines inherent in tumors - for each anatomical system, good medical practices and the data from Fig. 1.,
we conclude that the treatment of oncological diseases should be carried out in four stages (Fig.2.):
Figure 2 Schematic representation of the sequence of treatment with amide and carboxyl derivatives
of natural nitrile glycosides of cancer cell lines
- “shock therapy” - in the case of a primary diagnosis of the presence of oncological disease and/or
observation of pathological activity of cancer cells (including the growth of tumor tissues), the
patient should be treated with:
(R)-2-phenyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)acetamide
(R)-2-phenyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)acetic acid
"shock
therapy"
primary
treatment
synergistic
treatment
personalized
therapy
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
128
Thus, the active anticancer molecule released inside the cell itself will be ((R)-2-hydroxy-2-
phenylacetamide, which in turn would pass in a small amount into the carboxyl form - (R)-2-hydroxy-2-
phenylacetic acid (§IV.2.3.2.). Applying pharmaceutical form 1.B. (Tabl. 1.), the concentration of the
amide toxic to the cancer cell is 0.40 mg/ml, compared to the pharmaceutical oral form (§IV.2. 4., Tsanov
& Tsanov, 2023). Based on the analysis for determining the medicinal dose of the amide and carboxylic
derivatives of amygdalin (§IV.1. 3., Tsanov & Tsanov, 2023), it follows that the treatment dose for the
ratio, -amide: -carboxylic = 4.87: 1 is:
210-465 mg PO q6-8hr; not to exceed 2.1 g/day.
!!! If the patient shows allergic symptoms, he should undergo diuretic
cleansing, after consultation with a nephrologist - after which the treatment
should be started again. If similar symptoms appear again, this stage of
treatment can be skipped !!!
- primary treatment – after making the final diagnosis and determining the exact active cell lines,
the clinical oncologist must proceed to the actual treatment - Introduction of the main active
pharmaceutical form into the body.
This concept includes clinical selection from a pre-calculated set of substances active enough to
influence the physiological activity of the cancer cell. This stage aims to "attack" the cancer cells in a
wider range of cell lines, incl. those that overlap with other cancer formations (including metastases),
which at this moment may be in another stage of their development. The choice is made between the
chemical compounds from the Tabl. 6.
Table 4 Basic pharmaceutical forms for oral use for primary treatment of cancer, based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides
login
number*
active pharmaceutical forms for oral use**
UPAC component names
⁂
5.C.
(R)-2-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)tetrahydro-2H-
pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-
yl)oxy)methyl)tetrahydro-2H-pyran-2-
yl)oxy)butanamide
(R)-2-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)tetrahydro-2H-
pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-
yl)oxy)methyl)tetrahydro-2H-pyran-2-
yl)oxy)butanoic acid
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
129
56.B.
((2R,3S,4S,5R,6R)-6-(((2S,3R)-4-amino-3-
methyl-4-oxobutan-2-yl)oxy)-3,4,5-
trihydroxytetrahydro-2H-pyran-2-yl)methyl
(2S,3R)-2-ethyl-2,3-dihydroxybutanoate
(2R,3S)-3-(((2R,3R,4S,5S,6R)-6-((((2S,3R)-2-
ethyl-2,3-dihydroxybutanoyl)oxy)methyl)-3,4,5-
trihydroxytetrahydro-2H-pyran-2-yl)oxy)-2-
methylbutanoic acid
4.C.
2-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-
6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)methyl)tetrahydro-2H-pyran-2-
yl)oxy)methyl)tetrahydro-2H-pyran-2-
yl)oxy)propanamide
2-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-
6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)methyl)tetrahydro-2H-pyran-2-
yl)oxy)methyl)tetrahydro-2H-pyran-2-
yl)oxy)propanoic acid
40.
(Z)-2-((2S,3R,4S,6R)-2,3-dihydroxy-4-methoxy-
6-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)cyclohexylidene)acetamide
(Z)-2-((2S,3R,4S,6R)-2,3-dihydroxy-4-methoxy-
6-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)cyclohexylidene)acetic acid
63.
(2S,3R)-2-hydroxy-4-methoxy-1-methyl-6-oxo-3-
(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-
1,2,3,6-tetrahydropyridine-3-carboxamide
(2S,3R)-2-hydroxy-4-methoxy-1-methyl-6-oxo-3-
(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-
1,2,3,6-tetrahydropyridine-3-carboxylic acid
23.A.
2-(3-hydroxy-4-(((2S,3R,4R,5R,6S)-3,4,5-
trihydroxy-6-methyltetrahydro-2H-pyran-2-
yl)oxy)phenyl)acetamide
2-(3-hydroxy-4-(((2S,3R,4R,5R,6S)-3,4,5-
trihydroxy-6-methyltetrahydro-2H-pyran-2-
yl)oxy)phenyl)acetic acid
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
130
5.D.
(R)-2-(((2S,3R,4S,5S,6R)-6-
((((2R,3R,4R,5S,6R)-3,4-dihydroxy-6-
(hydroxymethyl)-5-(((2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)tetrahydro-2H-
pyran-2-yl)oxy)tetrahydro-2H-pyran-2-
yl)oxy)methyl)-3,4,5-trihydroxytetrahydro-2H-
pyran-2-yl)oxy)-2-methylbutanamide
(R)-2-(((2S,3R,4S,5S,6R)-6-
((((2R,3R,4R,5S,6R)-3,4-dihydroxy-6-
(hydroxymethyl)-5-(((2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)tetrahydro-2H-
pyran-2-yl)oxy)tetrahydro-2H-pyran-2-
yl)oxy)methyl)-3,4,5-trihydroxytetrahydro-2H-
pyran-2-yl)oxy)-2-methylbutanoic acid
19.
(2S,3S)-2-hydroxy-4-methoxy-1-methyl-6-oxo-3-
(((2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-
1,2,3,6-tetrahydropyridine-3-carboxamide
(2S,3S)-2-hydroxy-4-methoxy-1-methyl-6-oxo-3-
(((2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-
1,2,3,6-tetrahydropyridine-3-carboxylic acid
31.B.
(R)-2-(3-hydroxy-4-methoxyphenyl)-2-
(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)methyl)tetrahydro-2H-pyran-2-
yl)oxy)acetamide
(R)-2-(3-hydroxy-4-methoxyphenyl)-2-
(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)methyl)tetrahydro-2H-pyran-2-
yl)oxy)acetic acid
51.A.
(Z)-2-(hydroxymethyl)-4-(((2R,3R,4S,5S,6R)-
3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-
2H-pyran-2-yl)oxy)but-2-enamide
(Z)-2-(hydroxymethyl)-4-(((2R,3R,4S,5S,6R)-
3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-
2H-pyran-2-yl)oxy)but-2-enoic acid
56.A.
((2R,3S,4S,5R,6R)-6-(((2R,3S)-4-amino-3-
methyl-4-oxobutan-2-yl)oxy)-3,4,5-
trihydroxytetrahydro-2H-pyran-2-yl)methyl
(2S,3R)-2-ethyl-2,3-dihydroxybutanoate
(2S,3R)-3-(((2R,3R,4S,5S,6R)-6-((((2S,3R)-2-
ethyl-2,3-dihydroxybutanoyl)oxy)methyl)-3,4,5-
trihydroxytetrahydro-2H-pyran-2-yl)oxy)-2-
methylbutanoic acid
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
131
34.
(R)-3-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)tetrahydro-2H-
pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-
yl)oxy)but-3-enamide
(R)-3-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)tetrahydro-2H-
pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-
yl)oxy)but-3-enoic acid
*- sorted by general activity - descending
**- this table represents a sample of Tabl. 2 and the data from §IV.4. 2. of (Tsanov & Tsanov, 2023)
⁂- it is the most active isomeric molecular form. Any kind of optical isomerism is allowed.
The clinical approach here requires the selection of an active pharmaceutical form (Tabl. 6) against
the Interpretable prediction of sensitivity to active anticancer molecular forms of transcriptomic cell
lines intrinsic to tumors. Here the rule of greater activity is observed.
EXAMPLE:
for leukemia (§FINAL RESULTS/ Leukemia):
- basic potential medicines: AACF 1.C., 4.C., 5.C., 5.D., 19., 23.A., 25., 30.,
31.B., 31.C., 34., 36., 37., 38., 39., 40., 45.E., 46., 50., 56.A., 56.B. 57. and 63.;
- duplication of treatment and / or substitution on medical grounds: AACF 1.D., 1.G., 4.A., 4.B.,
5.A., 5.B., 7., 12., 31.A., 32., 33., 41., 42., 43., 44., 45.B., 47., 48., 49., 50., 51.A., 51.B., 60., 61.A.,
61.B., 62.B. and 64.
According to Tabl. 6 it follows that the choice of be:
- basic potential medicines: AACF 5.C. /in this case the 1st of general activity/;
and Tabl. 7 then:
- duplication of treatment and / or substitution on medical grounds: AACF 48.
/in this case third in overall activity /.
Table 5 Substitute pharmaceutical forms for oral use for primary treatment of cancer, based on
amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides
login
number*
active pharmaceutical forms for oral use**
UPAC component names
⁂
48.
(Z)-2-carbamoyl-4-(((2R,3R,4S,5S,6R)-
3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)but-2-en-1-yl (E)-3-(4-
hydroxyphenyl)acrylate
(Z)-2-((((E)-3-(4-
hydroxyphenyl)acryloyl)oxy)methyl)-4-
(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)but-2-enoic acid
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
132
44.
(Z)-4-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-
6-(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)but-2-enamide
(Z)-4-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-
6-(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)but-2-enoic acid
1.D.
(R)-2-phenyl-2-(((2S,3R,4R,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)tetrahydro-
2H-pyran-2-yl)oxy)acetamide
(R)-2-phenyl-2-(((2S,3R,4R,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)tetrahydro-
2H-pyran-2-yl)oxy)acetic acid
55.
2-((S)-2-oxo-3-(((2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)tetrahydro-
2H-pyran-2-yl)oxy)-2,3-dihydrobenzofuran-
3-yl)acetamide
2-((S)-2-oxo-3-(((2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)tetrahydro-
2H-pyran-2-yl)oxy)-2,3-dihydrobenzofuran-
3-yl)acetic acid
1.C.
(R)-2-phenyl-2-(((2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-((((2S,3R,4S,5R)-3,4,5-
trihydroxytetrahydro-2H-pyran-2-
yl)oxy)methyl)tetrahydro-2H-pyran-2-
yl)oxy)acetamide
(R)-2-phenyl-2-(((2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-((((2S,3R,4S,5R)-3,4,5-
trihydroxytetrahydro-2H-pyran-2-
yl)oxy)methyl)tetrahydro-2H-pyran-2-
yl)oxy)acetic acid
46.
(Z)-2-carbamoyl-4-(((2R,3R,4S,5S,6R)-
3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)but-2-en-1-yl 4-hydroxybenzoate
(Z)-2-(((4-hydroxybenzoyl)oxy)methyl)-4-
(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)but-2-enoic acid
33.
(R)-2-(hydroxymethyl)-2-
(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)butanamide
(R)-2-(hydroxymethyl)-2-
(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)butanoic acid
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
133
59.
(S)-4-amino-2-methylene-4-oxo-3-
(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)butyl 4-hydroxybenzoate
(S)-3-(((4-hydroxybenzoyl)oxy)methyl)-2-
(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)but-3-enoic acid
45.E.
(2R,3R,4S,5R,6R)-2-(((Z)-4-amino-2-
methyl-4-oxobut-2-en-1-yl)oxy)-3,5-
dihydroxy-6-(hydroxymethyl)tetrahydro-
2H-pyran-4-yl acetate
(Z)-4-(((2R,3R,4S,5R,6R)-4-acetoxy-3,5-
dihydroxy-6-(hydroxymethyl)tetrahydro-
2H-pyran-2-yl)oxy)-3-methylbut-2-enoic
acid
4.A.
2-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)tetrahydro-
2H-pyran-2-yl)oxy)propanamide
2-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)tetrahydro-
2H-pyran-2-yl)oxy)propanoic acid
42.
2-((2S,4aR,6S,8S,8aR)-8-hydroxy-6-
(hydroxymethyl)hexahydro-6H-pyrano[2,3-
b][1,4]dioxin-2-yl)acrylamide
2-((2S,4aR,6S,8S,8aR)-8-hydroxy-6-
(hydroxymethyl)hexahydro-6H-pyrano[2,3-
b][1,4]dioxin-2-yl)acrylic acid
*- sorted by general activity – descending
**- this table represents a sample of Tabl. 2 and the data from §IV.4. 2. of (Tsanov & Tsanov, 2023)
⁂- it is the most active isomeric molecular form. Any kind of optical isomerism is allowed.
If for some reason (financial, logistical, allergic, etc.) the first form cannot be used, then the next
molecular form is chosen and so on. The same applies if the activity is too great and this leads to
complications in other diseases (including chronic ones for the patient). Then apply (with the same
selection) – the substitute per oral pharmaceutical forms in the main treatment of cancer (Tabl. 7).
Based on the analysis for determining the medicinal dose of the amide and carboxylic derivatives
of amygdalin (§IV.1. 3., Tsanov & Tsanov, 2023), it follows that the treatment dose for the ratio, -
amide: -carboxylic = 4.87: 1 is:
210-655 mg PO q6-8hr; not to exceed 2.3 g/day.
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
134
!!! If the patient shows allergic symptoms, he should undergo diuretic
cleansing, after consultation with a nephrologist - after which the treatment
should be started again !!!
- synergistic treatment – the very genesis of the treatment we offer is based on chronification of
the disease, i.e. its transformation into controlled over time, by means of taking medicinal forms.
That is why there will inevitably come a time when the activity of the preparation will sharply
decrease. At this point, the body's clinical response will be directed against the treated substances. That's
why we have planned for a certain period of time to replace the medicinal products with those that will
preserve the overall activity. Medicinal substances are divided into two tables for each type of cancer,
according to §IV.4. 1. – conditionally accepted for Part 1 and Part 2. Thus, the clinical doctor can easily
select the substitute substances, observing the rule of substitutability according to tables, i.e. if he has
chosen a medicinal form from the table. with a Part 1 title, he makes a choice with a Part 2 title
(following exactly the same rules).
- Personalized therapy - in a small number of cases, it is necessary to act individually according to
the patient's current anamnesis. For this purpose, after the application of the general therapy and
/ or in combination with it, the specific agent for the respective cell lines must be taken (§.4.1.,
Tsanov & Tsanov, 2023). The ratio of amide to carboxylic acid should again be 4.87:1.
The doctor is only required to comply with the color assessment of activity (activity decreases in
order (§.III.3.4.1., Tsanov & Tsanov, 2023) - )
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
135
CLINICAL CONTROL
Correlation of bio constants
The bio constants of the human organism should not be accepted as a dogma, but simply used as
benchmarks of the norm. Deviation from them should not necessarily be considered pathology. The
human body adapts extremely well to the environment and strives to respond adequately to each
stimulus.
Especially when performing chemotherapy on cancer patients, it is necessary to monitor the overall
reference picture of the patient. It is good to avoid interpreting individual deviations from the
physiologically healthy organism and to direct the treatment of cancer in the direction of "suppression"
of individual symptoms.
In Tabl. 5 the control forms that the clinician must comply with before and during chemotherapy
are indicated. These are reference correlations that would directly affect the release of the active
anticancer molecular form (Tabl. 2) within the cancer cell.
A. VOLUME OF BLOOD: it is directly related to the fluid ratio, and secondarily to the water
content in the body - hence the change in a number of physicochemical parameters
When the total blood volume increases, it is important for the treating physician to rule out diagnoses:
- chronic leucosis;
- uremia (due to the change in nitrogen balance, which will prevent the transport of amide
derivatives in the body) - is often accompanied by hyperkalemia and hyperchloremia.
When the total blood volume decreases, it is necessary to exclude the diagnoses:
- acidosis - increased water content is also reported;
- tubular acidosis - IMPORTANT: do not rush with tenal tubular acidosis - there may also be
hypophosphatemia.
B. HEMATOCRIT:
In case of a decrease in the value of the hematocrit in the blood, it is obligatory for the attending
physician to reject the diagnoses:
- spherocytic anemia - at the beginning of treatment with amide / carboxylic derivative of nitrile
glycosides there is a !!! REAL POSSIBILITY FOR CRISIS !!! ;
- this condition is often an indicator of brain metastases.
C. NATREMIA:
Particular attention should be paid to cases of hyponatremia. Here the attending physician needs
to comply with diagnoses such as:
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
136
- cystic fibrosis (CP) / mucoviscidose/- in these cases treatment should begin with a very low
concentration of the dosage form;
- this condition is often an indicator of lung cancer.
D. KALEMIA:
To some extent, hyperkalemia has a synergistic effect on the action of the studied dosage forms. It
is good for the doctor to maintain higher blood potassium reference values. In cases where this is
difficult, two circumstances must be taken into account:
- to reject Cushing's syndrome, by control test and for hyperchloremia - gives both increase and
decrease;
- is often observed together with hypophosphatemia. If necessary, to introduce phosphorus
preparations into the body.
Table 6
E. CHLORAEMIA:
Hypochloraemia alters the ionic and electrostatic activity of both amides and carboxylic acids -
especially when they are in low concentrations in the blood. It is good to consider:
- presence of liver cirrhosis - the analysis should be done at least 4 hours after glucose infusion
and diuretics taken. The results should be differentiated from Hepato-renal syndrome.
F. CALCEMIA:
Hypercalcemia can suppress the spread of the drug form. Treatment should be resected and any
comorbidities considered:
- extensive metastases;
- osteorenal sarcoma;
- breast carcinoma with bone metastases during treatment with ANDROGENS and ESTRONES;
- sarcoidosis.
G. SIDERINEMIA:
Hyposiderinemia could delay the detection of a more acidic environment around the cancer cell
and from there slow down the action of the drug under study. The clinician should be aware that this is
often accompanied by:
- ballast leukemia;
- carcinomas;
- uterine fibroids;
- myelosis and lymphadenosis (in terminal stage);
- erythraemia vera (in terminal stage).
Correction of iron in the blood is one of the most important factors in treatment with these doses.
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
137
Table 7 Correlation data of microcomponents in human blood that affect the digestibility and activity
of amides and carboxylic acids derivatives of natural nitrile glycosides
control form
raise
reduction
indicator
indicator control
indicator
indicator control
volume of blood
chronic leucosis
acidosis
increased water
content is also
reported
tubular acidosis*
hypophosphatemia
uremia⁑
hyperkalemia
hyperchloremia
hematocrit
spherocytic anemia ☼
indicator of brain metastases
natremia▲
Mucoviscidose ⁂
indicator of lung cancer
kalemia
to reject Cushing's syndrome◊
often seen with hypophosphatemia
chloraemia
indicator and of liver cirrhosis§
calcemia
extensive metastases
osteorenal sarcoma
breast carcinoma with bone metastases
during treatment with ANDROGENS
and ESTROGENES
sarcoidosis
siderinemia
ballast leukemia
carcinomas
uterine fibroids
myelosis and lymphadenosis (in terminal
stage)
erythraemia vera (in terminal stage)
total iron-binding
capacity
bone marrow
hypoplasia
hemosiderosis
malignant tumors
cupremia
malignant tumors
increase in iodine
in the blood
malignant
melanoma
hemochromatosis
malignant
hemopathy (T-
leucosis)
increase of sulfates
in the blood
meligenic
lymphomas
treatment with
estrogen
cirrhosis of the
liver
reduction of iodine
in the blood
Zinc content in the
blood
in the serum
erythraemia vera
bone marrow hypoplasia
atrophic cirrhosis of the liver
lymphadenosis
acute leucosis
myelosis
in erythrocytes
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
138
bone marrow hypoplasia
myelosis
erythraemia vera
lifadenosis
*- IMPORTANT: do not rush with tenal tubular acidosis - there may also be hypophosphatemia
⁑- due to a change in the nitrogen balance
☼- REAL POSSIBILITY FOR CRISIS !
⁂- MANDATORY- the treatment should begin with a very low concentration of the dosage form
▲- to rule out myxedema as a concomitant disease
◊- control test and for hyperchloremia - gives both increase and decrease
§- the analysis should be performed at least 4 hours after glucose infusion and diuretics taken. The results
should be differentiated from Hepato-renal syndrome
H. TOTAL IRON-BINDING CAPACITY
In case of increased content of total iron-binding capacity, it is necessary for the clinician to take
into account the possible presence of:
- bone marrow hypoplasia,
and at reduced content with:
- hemosiderosis;
- malignant tumors.
I. CUPREMIA:
Hypercupremia would significantly increase the need for a higher drug dose. She herself is also an
indicator for:
- malignant tumors - as an control sample can be used and the increase in iodine in the blood; -
malignant melanoma;
- hemochromatosis;
- malignant hemopathy (T-leukemia) - as an control sample can be used and the increase of sulfates
in the blood;
- meligenic lymphomas;
- treatment with estrogen;
- cirrhosis of the liver - as a control sample can be used and the reduction of iodine in the blood.
J. ZINC CONTENT IN THE BLOOD
The content of zinc in the blood determines its extremely complex role in cancer. Its compounds
are both inhibitors and promoters. It can displace a number of metals from organometallic biologically
active substances, but at the same time its coordination compounds in an in vivo medium are volatile.
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
139
We recommend a mandatory blood test for zinc in the blood before starting chemotherapy
according to the studied experimental methodology. The following reference deviations must be taken
into account:
a. in the serum:
increased serum zinc concentration:
decreased serum zinc concentration:
- erythraemia vera;
- atrophic cirrhosis of the liver;
- acute leukemia.
- bone marrow hypoplasia;
- lymphadenosis;
- myelosis.
b. in erythrocytes:
increased concentration of zinc in
erythrocytes:
decreased concentration of zinc in
erythrocytes:
- bone marrow hypoplasia;
- erythraemia vera.
- myelosis;
- lifadenosis.
Chemoprevention and Homeopathy
The proposed methodological program for conservative treatment of oncological diseases does not
contradict the good medical practices for chemotherapy. In order to improve the general condition of
patients, chemoprevention (Lele, 2021) and/or homeopathy could be applied, but not at the expense of
a varied diet, incl. table salt, water, culinary acidifiers and fats. Alternative medicine should only be used
to treat individual symptoms, not syndromes.
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
140
THE CONCLUSIONS OF THE PREVIOUS STUDIES
On the first goal (Tsanov & Tsanov, 2020)
Our legacy of the Hunza people and the knowledge from tens-of-thousands of scientists who
created modern synthesis and biochemistry make the production of nitrile amide into a routine
(especially with nitrile hydratase). Thus, humanity holds in its hands a huge medicinal resource that can
provide treatment for diseases of all parts of conservative medicine (including all listed in Section 1.1.).
The hydrolyzed to amide/carboxylic acid nitrile/cyanide carbohydrates will occupy one of the
fundamental steps of countless future clinical practices. This is the purpose of our modest research!
Other substances in these groups with pronounced biological activity (including anti-tumor) are
the hydrolyzed nitrile groups of Linamarin, (R) -Lotaustralin, S-Sambunigrin, etc., to their
amide/carboxylic acid.
The second goal (Tsanov & Tsanov, 2021)
1) The amide derivatives of nitrile glycosides are potential chemical compounds with anti-cancer
activity;
2) the cancer cell seeks to shift the hydrolysis of these derivatives in a direction that would not pass
through its cell membrane;
3) the amide-carboxylic derivatives of nitrile glycosides can deliver extremely toxic compounds
inside the tumor cell itself and thus block and / or permanently damage its normal physiology;
4) the use of these compounds in oncology could turn cancer from a lethal to a chronic disease (such
as diabetes). The cause and conditions of the disease are not eliminated, but the number of cancer
cells could be kept low for a long time (even a lifetime).
On the third goal (Tsanov & Tsanov, 2022)
1) Amides resulting from the hydrolysis of nitrile glycosides would be able to cross the cell
membrane of a cancer cell and thus cause its cellular response;
2) the pharmaceutical form must represent the exact amide/carboxylic acid ratio for the
corresponding active anticancer cell form;
3) clinical concentrations are more than 7 times higher than those of nitrile glycosides due to their
reduced toxicity;
4) no significant deviations are observed, on a theoretical level, in the complex use of several
pharmaceutical forms together and/or sequentially.
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
141
AUTHOR'S NOTES
With the present scientific work, we have tried to present in a more generalized form our long-
term theoretical research. We tried to draw every value, every dependence and every conclusion
precisely, in a form that is not subject to any personal view and/or to be enslaved to a generally
"accepted" opinion.
Natural nitrile glycosides would not cross the tumor cell membrane. They decompose to HCN-
acid, phenyl methanol and carbohydrate. They do NOT have antitumor activity due to their inability to
reach the target unchanged. These compounds, in their natural form, are extremely toxic to the human
body. Applying them is not a cure, even at higher concentrations they do more harm than good.
Theoretically, we have derived dozens of their modified forms, but their amides and carboxylic acids
are the most promising for their introduction in conservative oncology. The fact is that the tumor cell
itself is trying to counteract in a way that is quite safe for it.
The knowledge that humanity has gained from the millennial battle between it and tumors,
combined with the development of mathematics, statistical and quantum molecular thermodynamics,
molecular topology and geometry, clinical oncology, pathophysiology, etc., with the unequivocal
contribution of thousands of scientists, we tried to we present this thesis as a sentence and the most
modest way to try to confirm and prove it.
- ◊ -
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
142
ETHICS APPROVAL AND CONSENT TO PARTICIPATE
Not applicable.
HUMAN AND ANIMAL RIGHTS
No Animals/Humans were used for studies that are the basis of this research.
CONSENT FOR PUBLICATION
Not applicable.
AVAILABILITY OF DATA AND MATERIALS
The authors confirm that the data supporting the findings of this study are available within the article.
FUNDING
None.
CONFLICT OF INTEREST
The authors declare no conflict of interest, financial or otherwise.
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
143
REFERENCES
Cadow, J., Born, J., Manica, M., Oskooei, A., & Martínez, M. R. (2020). PaccMann: a web service for
interpretable anticancer compound sensitivity prediction. Nucleic Acids Research, 48(W1), W502-8.
doi:10.1093/nar/gkaa327
Christopher, A. (2017). Drawing conclusions from data: descriptive statistics, inferential statistics, and
hypothesis testing, In Interpreting and using statistics in psychological research. SAGE Publications Inc.
doi:10.4135/9781506304144
Dimitrov, S. D., Diderich, R., Sobanski, T., Pavlov, T. S., Chankov, G., Chapkanov, A., . . . Mekenyan,
O. (2016). QSAR Toolbox – workflow and major functionalities. SAR and QSAR in Environmental
Research, 27(3), 203-19. doi:10.1080/1062936X.2015.1136680
Gary, W. C., Zhengyin, Y., Wensheng, L., & Masucci, A. (2012). The IC50 Concept Revisited. Current
Topics in Medicinal Chemistry, 12(11). doi:10.2174/156802612800672844
Ghandi, M., Huang, F. W., & Jané-Valbuena, J. (2019). Next-generation characterization of the Cancer
Cell Line Encyclopedia. Nature, 569, 503-8. doi:10.1038/s41586-019-1186-3
Hubert, M., & Vandervieren, E. (2008). An adjusted boxplot for skewed distributions. Computational
Statistics & Data Analysis, 52(12), 5186-201. doi:10.1016/j.csda.2007.11.008
Legras, J., Chuzel, G., Arnaud A., Galzy, P. (1990). Natural nitriles and their metabolism. World Journal
of Microbiology and Biotechnology, 6, 83-108 , doi:10.1007/BF01200927
Marmolejo-Ramos, F., & Tian, T. (2010). he shifting boxplot. A boxplot based on essential summary
statistics around the mean. International Journal of Psychological Research, 3(1), 37-45.
doi:10.21500/20112084.823
Sebaugh, J. L. (2011). Guidelines for accurate EC50/IC50 estimation. Pharmaceutical Statistics, 10, 128-
34. doi:10.1002/pst.426
Soares, J., Greninger, P., Yang, W., Edelman, E. J., Lightfoot, H., Forbes, S., . . . Garnett, M. (2013).
Genomics of Drug Sensitivity in Cancer: a resource for therapeutic biomarker discovery in cancer cells.
Nucleic Acids Research, 41(D1), D955-61. doi:10.1093/nar/gks1111
Tsanov, V., Tsanov, H., Theoretical Analysis for the Safe Form and Dosage of Amygdalin Product,
Anti-Cancer Agents in Medicinal Chemistry 2020; 20(7), DOI: 10.2174/1871520620666200313163801
Tsanov, V., Tsanov, H., Theoretical Analysis of Anticancer Cellular Effects of Glycoside Amides, Anti-
Cancer Agents in Medicinal Chemistry 2022; 22(6), DOI: 10.2174/1871520621666210903122831
Tsanov, V., Tsanov, H., Theoretical Study of the Process of Passage of Glycoside Amides through the
Cell Membrane of Cancer Cell, Anti-Cancer Agents in Medicinal Chemistry 2021; 21(12), DOI:
10.2174/1871520620999201103201008
Tsanov, V.; Tsanov, H.,Theoretical study of anticancer activity of glycoside amides [ third supplemented
edition ], pp. 857, ISBN: 978-619-91534-4-4, DOI: 10.5281/zenodo.7295357
Yordanova, D., Schultz, T., Kuseva, C., Tankova, K., Ivanova, H., Dermen, I., . . . Mekenyan, O. (2019).
Automated and standardized workflows in the OECD QSAR Toolbox. Computational Toxicology, 10,
89-104. doi:10.1016/j.comtox.2019.01.006
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
144
CONTENTS OF FIGURES AND TABLES
FIGURE 1 SCHEMATIC REPRESENTATION OF THE DESCRIPTIVE DEPENDENCES OF THE INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE
PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE
THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF
TRANSCRIPTOME CELL LINES INHERENT IN TUMORS .................................................................................................................. 126
FIGURE 2 SCHEMATIC REPRESENTATION OF THE SEQUENCE OF TREATMENT WITH AMIDE AND CARBOXYL DERIVATIVES OF NATURAL NITRILE
GLYCOSIDES OF CANCER CELL LINES....................................................................................................................................... 127
TABLE 1 ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE ANTI-CANCER MOLECULES OBTAINED AFTER PASSAGE
THROUGH THE CELL MEMBRANE, BASED ON HYDROLYZED AMIDE/CARBOXYLIC ACID DERIVATIVES OF NATURAL NITRILE GLYCOSIDES ........... 10
TABLE 2 ACTIVE APOPTOTIC AMIDE/CARBOXYLIC ACID MOLECULAR FORMS, BASED ON HYDROLYZED AMIDE/CARBOXYLIC ACID DERIVATIVES OF
NATURAL NITRILE GLYCOSIDES ............................................................................................................................................... 29
TABLE 3 NATURE AND CONCENTRATION OF ACTIVE ANTICANCER CELL MOLECULES OBTAINED AFTER CROSSING THE CELL MEMBRANE BY THEIR
NATURAL PRECURSORS ........................................................................................................................................................ 33
TABLE 4.1. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE AERODIGESTIVE TRACT: PART 1
...................................................................................................................................................................................... 38
TABLE 4.1. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE AERODIGESTIVE TRACT: PART 2
...................................................................................................................................................................................... 39
TABLE 4.2. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE AUTONOMIC GANGLION: PART
1 .................................................................................................................................................................................... 41
TABLE 4.2. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE AUTONOMIC GANGLION: PART
2 .................................................................................................................................................................................... 41
TABLE 4.3. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE BILIARY TRACT: PART 1 ....... 43
TABLE 4.3. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE BILIARY TRACT: PART 2 ....... 43
TABLE 4.4. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE BONE: PART 1 ................... 44
TABLE 4.4. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE BONE: PART 2 ................... 45
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
145
TABLE 4.5. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE BREAST: PART 1 ................ 47
TABLE 4.5. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE BREAST: PART 2 ................ 49
TABLE 4.6. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE CENTRAL NERVOUS SYSTEM:
PART 1 ............................................................................................................................................................................. 51
TABLE 4.6. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE CENTRAL NERVOUS SYSTEM:
PART 2 ............................................................................................................................................................................. 52
TABLE 4.7. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE DIGESTIVE SYSTEM: PART 1 .. 54
TABLE 4.7. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE DIGESTIVE SYSTEM: PART 2 .. 55
TABLE 4.8. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE ENDOMETRIUM: PART 1 ...... 56
TABLE 4.8. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE ENDOMETRIUM: PART 2 ...... 57
TABLE 4.9. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE HEMATOPOIETIC AND
LYMPHOID TISSUES: PART 1 .................................................................................................................................................. 58
TABLE 4.9. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE HEMATOPOIETIC AND
LYMPHOID TISSUES: PART 2 .................................................................................................................................................. 61
TABLE 4.10. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE KIDNEY: PART 1 ................. 64
TABLE 4.10. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE KIDNEY: PART 2 ................. 65
TABLE 4.11. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE LARGE INTESTINE: PART 1 .... 67
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
146
TABLE 4.11. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE LARGE INTESTINE: PART 2 .... 69
TABLE 4.12. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE LEUKEMIA: PART 1 ............. 71
TABLE 4.12. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE LEUKEMIA: PART 2 ............. 72
TABLE 4.13. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE LIVER: PART 1 ................... 74
TABLE 4.13. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE LIVER: PART 2 ................... 75
TABLE 4.14. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE LUNG: PART 1 ................... 76
TABLE 4.14. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE LUNG: PART 2 ................... 81
TABLE 4.15. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE LYMPHOMA: PART 1........... 87
TABLE 4.15. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE LYMPHOMA: PART 2........... 88
TABLE 4.16. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE MYELOMA: PART 1 ............ 90
TABLE 4.16. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE MYELOMA: PART 2 ............ 91
TABLE 4.17. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE NEUROBLASTOMA: PART 1 .. 92
TABLE 4.17. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE NEUROBLASTOMA: PART 2 .. 93
TABLE 4.18. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE NERVOUS SYSTEM: PART 1 .. 94
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
147
TABLE 4.18. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE NERVOUS SYSTEM: PART 2 .. 95
TABLE 4.19. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE OESOPHAGUS: PART 1 ........ 97
TABLE 4.19. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE OESOPHAGUS: PART 2 ........ 98
TABLE 4.20. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE OVARY: PART 1 ................. 99
TABLE 4.20. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE OVARY: PART 2 ............... 100
TABLE 4.21. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE PANCREAS: PART 1........... 101
TABLE 4.21. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE PANCREAS: PART 2........... 102
TABLE 4.22. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE PLEURA: PART 1 .............. 104
TABLE 4.22. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE PLEURA: PART 2 .............. 104
TABLE 4.23. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE PROSTATE: PART 1 ........... 105
TABLE 4.23. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE PROSTATE: PART 2 ........... 105
TABLE 4.24. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE SALIVARY GLAND: PART 1 .. 106
TABLE 4.24. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE SALIVARY GLAND: PART 2 .. 106
TABLE 4.25. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE SKIN: PART 1 .................. 107
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
148
TABLE 4.25. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE SKIN: PART 2 .................. 109
TABLE 4.26. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE SMALL INTESTINE: PART 1 .. 111
TABLE 4.26. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE SMALL INTESTINE: PART 2 .. 111
TABLE 4.27. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE SOFT TISSUE: PART 1 ........ 112
TABLE 4.27. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE SOFT TISSUE: PART 2 ........ 113
TABLE 4.28. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE STOMACH: PART 1 ........... 114
TABLE 4.28. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE STOMACH: PART 2 ........... 115
TABLE 4.29. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE THYROID: PART 1 ............. 116
TABLE 4.29. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE THYROID: PART 2 ............. 117
TABLE 4.30. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE UPPER AERODIGESTIVE TRACT:
PART 1 ........................................................................................................................................................................... 118
TABLE 4.30. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE UPPER AERODIGESTIVE TRACT:
PART 2 ........................................................................................................................................................................... 119
TABLE 4.31. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE URINARY TRACT: PART 1 ... 120
TABLE 4.31. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE URINARY TRACT: PART 2 ... 121
TABLE 4.32. A INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
Vasil Tsanov & Hristo Tsanov
149
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE UROGENITAL SYSTEM: PART 1
.................................................................................................................................................................................... 122
TABLE 4.32. B INTERPRETABLE PROGNOSIS OF SENSITIVITY TO ACTIVE PHARMACEUTICAL FORMS FOR ORAL USE AND THEIR CORRESPONDING ACTIVE
ANTI-CANCER MOLECULES (OBTAINED AFTER PASSAGE THROUGH THE CELL MEMBRANE), BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES, OF TRANSCRIPTOME CELL LINES INHERENT IN TUMORS IN THE UROGENITAL SYSTEM: PART 2
.................................................................................................................................................................................... 124
TABLE 5 CORRELATION DATA OF MICROCOMPONENTS IN HUMAN BLOOD THAT AFFECT THE DIGESTIBILITY AND ACTIVITY OF AMIDES AND CARBOXYLIC
ACIDS DERIVATIVES OF NATURAL NITRILE GLYCOSIDES ............................................................................................................... 137
TABLE 6 BASIC PHARMACEUTICAL FORMS FOR ORAL USE FOR PRIMARY TREATMENT OF CANCER, BASED ON AMIDES/CARBOXYLIC ACIDS - HYDROLYSIS
DERIVATIVES OF NATURAL NITRILE GLYCOSIDES ....................................................................................................................... 128
TABLE 7 SUBSTITUTE PHARMACEUTICAL FORMS FOR ORAL USE FOR PRIMARY TREATMENT OF CANCER, BASED ON AMIDES/CARBOXYLIC ACIDS -
HYDROLYSIS DERIVATIVES OF NATURAL NITRILE GLYCOSIDES ....................................................................................................... 131
HTML5 version of DOI: 10.5281/zenodo.13777292 | https://anti-cancer.eu
ATLAS
Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
/ Second supplemented edition /
150
Let the preferred version of reading this book be electronic.
Print something really urgent on your recycled paper and printer toner!
This book is constructed in a structure aimed at limiting animal testing in
laboratory and preclinical settings.
Only refurbished computers, tablets and smart devices were used in the
creation of this book. Good practices have also been applied to reduce
energy consumption. The goal is to prevent additional carbon load in the
world around us.
Full calculations are posted here*:
Tsanov, V., Tsanov, H. (2024). Interpretable prediction for anticancer sensitivity of glycoside amides
(Version 2) [Data set], Zenodo, DOI: 10.5281/zenodo.13777312
*- the information is constantly updated - choose the current version at the moment
“SAVE TREE” LOGO - HTTPS://WWW.CLIPARTMAX.COM/MIDDLE/M2I8Z5K9K9Z5A0B1_SAVE-TREE-FREE-DOWNLOAD-PNG-SAVE-TREE-LOGO/
“BUNNY – CRUELTY FREE” LOGO - HTTPS://WWW.PNGWING.COM/EN/FREE-PNG-IZVHK
i
Bibl - King James Version (KJV)
